[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1129
1. van Baal JW, Milana F, Rygiel AM, Sondermeijer CM, Spek CA, Bergman JJ, Peppelenbosch MP, Krishnadath KK: A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma. Cell Oncol; 2008;30(1):63-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma.
  • Esophageal adenocarcinoma (EA) and esophageal squamous cell carcinoma (ESCC) are the two main types of esophageal cancer.
  • Therefore we evaluated the transcriptome of EA in comparison to non-dysplastic Barrett's esophagus (BE), the metaplastic epithelium that predisposes for EA, and compared the transcriptome of ESCC to normal esophageal squamous epithelium.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Gene Expression Profiling
  • [MeSH-minor] Aged. Aged, 80 and over. Barrett Esophagus / genetics. Esophagus / metabolism. Female. Humans. Immunoblotting. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219111.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4618979
  •  go-up   go-down


2. Trakál E, Guidi A, Butti AL, Trakál JJ, Sambuelli R, Zárate FE: Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67). Acta Gastroenterol Latinoam; 2010 Sep;40(3):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
  • The rising incidence of adenocarcinoma in Barrett's esophagus has intensified the research into methods of early recognition of cancer risk, detecting cytological and architectural changes (dysplasia) or using biomarkers as predictive tests.
  • The aim of this paper is to evaluate the involvement of two tumor markers: p53 (tumor suppressor gene) and Ki67 (proliferation marker), by means of immunohistochemical analysis with monoclonal antibodies designed for the specific localization of p53 and Ki67 antigens, in esophageal biopsies with columnar metaplasia of patients with and without dysplasia and adenocarcinoma, and to anticipate which ones are liable to suffer it in the future.
  • Both markers were positive in all intestinal metaplasia patients with high-grade dysplasia and adenocarcinoma, and even in some cases with low grade or without dysplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Biomarkers, Tumor / analysis. Esophageal Neoplasms / pathology. Ki-67 Antigen / analysis. Precancerous Conditions / pathology. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049770.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


3. Avissar NE, Toia L, Hu Y, Watson TJ, Jones C, Raymond DP, Matousek A, Peters JH: Bile acid alone, or in combination with acid, induces CDX2 expression through activation of the epidermal growth factor receptor (EGFR). J Gastrointest Surg; 2009 Feb;13(2):212-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Bile acids and acid are implicated in the development of Barrett's esophagus.
  • Evidence suggests that Barrett's esophagus intestinal metaplasia may occur via induction of caudal homeobox gene 2 (CDX2).
  • The molecular pathogenesis of Barrett's esophagus may occur via bile-stimulated cell signaling through the EGFR.
  • [MeSH-major] Adenocarcinoma / metabolism. Deoxycholic Acid / pharmacology. Epithelial Cells / drug effects. Esophageal Neoplasms / metabolism. Homeodomain Proteins / metabolism. Receptor, Epidermal Growth Factor / drug effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biophys J. 2003 Oct;85(4):2732-45 [14507736.001]
  • [Cites] Oncogene. 2006 Dec 7;25(58):7565-76 [16785991.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16045-50 [11278982.001]
  • [Cites] Dis Esophagus. 2006;19(4):260-6 [16866857.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2009-31 [16344068.001]
  • [Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]
  • [Cites] J Surg Res. 2005 May 15;125(2):189-212 [15854673.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1042-55 [15825085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7565-70 [15894614.001]
  • [Cites] Scand J Gastroenterol. 2007 Dec;42(12 ):1460-5 [17852856.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):488-96 [16990345.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):985-93 [11910351.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6500-5 [12438243.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2033-6 [10445524.001]
  • [Cites] Gut. 1992 Apr;33(4):439-43 [1582583.001]
  • [Cites] EMBO J. 2002 Feb 1;21(3):303-13 [11823423.001]
  • [Cites] Mod Pathol. 2004 Oct;17 (10 ):1282-8 [15167938.001]
  • [Cites] J Gastrointest Surg. 2007 Jul;11(7):827-34 [17458588.001]
  • [Cites] Surgery. 2005 Nov;138(5):924-31 [16291394.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Nov;283(5):G1098-106 [12381523.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):154-9 [17214962.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1540-57 [15521021.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1191-206 [16618413.001]
  • [Cites] J Cell Sci. 2003 Apr 15;116(Pt 8):1429-36 [12640028.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4796-808 [12234920.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1012-9 [10362109.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(15):5380-94 [12101233.001]
  • [Cites] Prog Neurobiol. 1997 Jan;51(1):19-37 [9044427.001]
  • [Cites] Biochem Pharmacol. 2005 Oct 1;70(7):1035-47 [16139803.001]
  • [Cites] Gut. 2006 Jan;55(1):16-25 [16118348.001]
  • [Cites] J Cell Sci. 2001 Sep;114(Pt 17):3075-81 [11590234.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2629-45 [11553704.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9222-9 [10734059.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):1-17 [14766123.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):31214-9 [12063263.001]
  • [Cites] Biochem Pharmacol. 2007 Apr 1;73(7):1001-12 [17222808.001]
  • [Cites] J Cell Sci. 2006 Feb 1;119(Pt 3):571-81 [16443754.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):14948-60 [16547009.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G31-6 [12606307.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2167-78 [11493652.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 1):S2-6 [17449347.001]
  • [Cites] Hepatology. 2002 Feb;35(2):307-14 [11826403.001]
  • [Cites] Curr Opin Gastroenterol. 2004 Mar;20(2):70-6 [15703624.001]
  • [Cites] Surgery. 2005 Sep;138(3):415-21 [16213893.001]
  • (PMID = 18854960.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Ligands; 0 / RNA, Messenger; 005990WHZZ / Deoxycholic Acid; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


Advertisement
4. Gil J, Błaszak A, Wojtuń S, Wojtkowiak M: [Endoscopic methods of gastro-esophageal reflux disease (GERD) treatment and their complications]. Pol Merkur Lekarski; 2007 May;22(131):429-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic character of GERD is associated with intestinal metaplasia and adenocarcinoma of the esophagus in its distal part.
  • The most effective endoscopic methods of the treatment include: endoscopic dilation of the strictures and endoscopic methods of patological epithelium removal in Barrett's esophagus.
  • [MeSH-minor] Animals. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Fundoplication / methods. Humans. Laser Coagulation. Laser Therapy. Metaplasia. Monitoring, Ambulatory. Postoperative Complications. Proton Pump Inhibitors. Proton Pumps / drug effects

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679388.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors; 0 / Proton Pumps
  • [Number-of-references] 25
  •  go-up   go-down


5. Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, Blount PL, Odze RD, Ayub K, Reid BJ, Vaughan TL: Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer; 2008;60(1):39-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.
  • The incidence of esophageal adenocarcinoma (EA) and its precursor condition, Barrett's esophagus, has risen rapidly in the United States for reasons that are not fully understood.
  • Therefore, we evaluated the association between use of supplemental vitamins and minerals and risk of neoplastic progression of Barrett's esophagus and EA.
  • The Seattle Barrett's Esophagus Program is a prospective study based on 339 men and women with histologically confirmed Barrett's esophagus.
  • In this cohort study, use of multivitamins and single antioxidant supplements was associated with a significantly reduced risk of EA and markers of neoplastic progression among individuals with Barrett's esophagus.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):750-4 [10925371.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Am J Public Health. 2001 Feb;91(2):258-64 [11211635.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3467S-3470S [12421872.001]
  • [Cites] Blood Cells Mol Dis. 2002 Sep-Oct;29(2):174-8 [12490284.001]
  • [Cites] Nutr Cancer. 2002;44(2):104-26 [12734057.001]
  • [Cites] Am J Epidemiol. 2003 May 15;157(10):944-54 [12746248.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97 [12916666.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):339-49 [15286019.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):914-9 [15309877.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Comput Methods Programs Biomed. 1989 Sep;30(1):47-57 [2582746.001]
  • [Cites] Ann N Y Acad Sci. 1990;587:123-39 [2193564.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9 [1551528.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Gastroenterol Clin Biol. 1994;18(1 Pt 2):D31-4 [8013780.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):614-21 [8566611.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):33-40 [8850433.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Int J Oncol. 1998 Oct;13(4):855-64 [9735417.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Eur J Clin Nutr. 2005 Oct;59(10):1181-90 [16034362.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2559-66 [16380980.001]
  • [Cites] J Nutr. 2006 May;136(5):1359-64 [16614430.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Ann Intern Med. 2006 Sep 5;145(5):364-71 [16880454.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):215-22 [16887864.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):136-42 [16905748.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Nutr Cancer. 2000;36(1):7-13 [10798210.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • (PMID = 18444134.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA 94880; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / CA091955-010002; United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / R25 CA094880-01; United States / NCI NIH HHS / CA / P01 CA 91955; United States / NCI NIH HHS / CA / P01 CA091955-010002; United States / NCI NIH HHS / CA / CA094880-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vitamins; 1406-18-4 / Vitamin E; PQ6CK8PD0R / Ascorbic Acid
  • [Other-IDs] NLM/ NIHMS42900; NLM/ PMC2366201
  •  go-up   go-down


6. Shaheen NJ: Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology; 2005 May;128(6):1554-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in Barrett's esophagus and esophageal adenocarcinoma.
  • Despite advances in diagnosis and therapy, esophageal adenocarcinoma remains an aggressive and usually lethal tumor.
  • This review focuses on the epidemiology of esophageal adenocarcinoma and its presumed precursor lesion, Barrett's esophagus; the pathogenesis of the cancer; advances in treatment of adenocarcinoma and Barrett's esophagus; and strategies for cancer prevention.
  • Although the absolute number of cases of adenocarcinoma in the United States is still small, the incidence of this cancer has increased dramatically in the last 40 years, and adenocarcinoma is now the predominant form of esophageal cancer in this country.
  • Recent evidence suggests that Barrett's esophagus is more prevalent in asymptomatic individuals than previously appreciated.
  • The pathogenesis of Barrett's esophagus is poorly understood.
  • Given that some subjects will have repeated bouts of severe erosive esophagitis and never develop Barrett's esophagus, host factors must play an important role.
  • The utility of neoadjuvant radiation and chemotherapy in those with adenocarcinoma, although they are widely practiced, is not of clear benefit, and some authorities recommend against it.
  • The value of chemoprevention in subjects with dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors is unknown.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887151.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23DK59311-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 130
  •  go-up   go-down


7. Solaymani-Dodaran M, Logan RF, West J, Card T: Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol; 2005 Dec;100(12):2616-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study.
  • INTRODUCTION: Patients with Barrett's esophagus have a much increased risk of esophageal adenocarcinoma but recent evidence suggests no increase in overall mortality.
  • METHODS: Cohorts of patients having Barrett's esophagus (n=1,677), esophagitis (n=6,392), simple reflux (n=6,328), and a standard reference cohort representing the general population in the United Kingdom (n=13,416) were selected from General Practice Research Database.
  • The last three cohorts were matched to the Barrett's cohort by general practice, age, and sex.
  • Of 111 deaths in the Barrett's cohort, 13 (12%) were in subjects with esophageal cancer.
  • Compared with the reference cohort, hazard ratios for all causes of death were 1.37 (1.12-1.66) for the Barrett's, 1.16 (1.02-1.32) for the esophagitis, and 1.16 (1.01-1.33) for the reflux cohorts.
  • Of the excess mortality rates in the Barrett's, esophagitis, and reflux cohorts, at the most 45%, 20%, and 13%, respectively, could be attributed to esophageal cancer.
  • CONCLUSION: People with Barrett's esophagus and gastroesophageal reflux disease have higher mortality rates than the general population, and an increase in esophageal cancer risk accounts for less than half the excess mortality in Barrett's.
  • [MeSH-major] Barrett Esophagus / mortality. Barrett Esophagus / pathology. Esophageal Neoplasms / mortality. Gastroesophageal Reflux / mortality. Gastroesophageal Reflux / pathology. Precancerous Conditions / pathology


8. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, Anderson GJ, Spychal R, Iqbal T, Tselepis C: Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res; 2008 Jan 15;14(2):379-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma.
  • PURPOSE: There is growing evidence that iron is important in esophageal adenocarcinoma, a cancer whose incidence is rising faster than any other in the Western world.
  • In this study, we investigated the expression of iron transport proteins involved in cellular iron import, export, and storage in the premalignant lesion Barrett's metaplasia and esophageal adenocarcinoma.
  • EXPERIMENTAL DESIGN: Perls' staining was used to examine iron deposition in tissue. mRNA expression in samples of Barrett's metaplasia matched with esophageal adenocarcinoma and samples of Barrett's metaplasia without evidence of adenocarcinoma were examined by real-time PCR.
  • RESULTS: In the progression of Barrett's metaplasia to adenocarcinoma, there was overexpression of divalent metal transporter 1 (DMT1), transferrin receptor 1, duodenal cytochrome b, ferroportin, and H-ferritin, and these changes were associated with increased iron deposition.
  • Overexpression of DMT1 was further associated with metastatic adenocarcinoma.
  • CONCLUSIONS: Progression to adenocarcinoma is associated with increased expression of iron import proteins.
  • [MeSH-major] Adenocarcinoma / physiopathology. Barrett Esophagus / physiopathology. Cation Transport Proteins / metabolism. Esophageal Neoplasms / physiopathology. Iron / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223212.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD71 antigen; 0 / Cation Transport Proteins; 0 / Cytochrome b Group; 0 / Receptors, Transferrin; 0 / metal transporting protein 1; 0 / solute carrier family 11- (proton-coupled divalent metal ion transporters), member 2; 9013-31-4 / Apoferritins; E1UOL152H7 / Iron; EC 1.- / Oxidoreductases; EC 1.6.99.- / CYBRD1 protein, human
  •  go-up   go-down


9. Barr H, Stone N, Rembacken B: Endoscopic therapy for Barrett's oesophagus. Gut; 2005 Jun;54(6):875-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic therapy for Barrett's oesophagus.
  • [MeSH-major] Barrett Esophagus / surgery. Catheter Ablation / methods. Esophagoscopy / methods
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Clinical Trials as Topic. Disease Progression. Esophageal Neoplasms / pathology. Esophageal Neoplasms / prevention & control. Humans. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Risk Factors. Treatment Outcome

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):513-33, viii [14629107.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):112-27 [14653411.001]
  • [Cites] Gut. 1999 Oct;45(4):489-94 [10486353.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1289-96 [15606390.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):689-96 [11726843.001]
  • [Cites] Lasers Med Sci. 2002;17(1):51-6 [11845368.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):390-6 [11868015.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1085-91 [12362099.001]
  • [Cites] Gut. 2002 Nov;51(5):620-1 [12377793.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):128-35 [14653412.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):146-54 [14653414.001]
  • [Cites] Endoscopy. 2004 Apr;36(4):298-305 [15057678.001]
  • [Cites] Gut. 2004 May;53(5):634-40 [15082579.001]
  • [Cites] Gut. 2004 Jun;53(6):785-90 [15138203.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Gastrointest Endosc. 1976 Aug;23(1):29-30 [964582.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):93-6 [2302524.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62 [8454147.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):445-50 [8261986.001]
  • [Cites] Surgery. 1994 Feb;115(2):176-81 [8310406.001]
  • [Cites] Gastrointest Endosc. 1994 Mar-Apr;40(2 Pt 1):199-206 [8013822.001]
  • [Cites] Gastrointest Endosc. 1994 Mar-Apr;40(2 Pt 1):224-6 [8013827.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):63-72 [7541003.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):584-5 [8774572.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):68-72 [8836721.001]
  • [Cites] Gut. 1997 Jan;40(1):123-7 [9155589.001]
  • [Cites] Br J Surg. 1997 Oct;84(10):1470-3 [9361616.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):239-45 [9500226.001]
  • [Cites] Surgery. 1998 Apr;123(4):432-9 [9551070.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):8-12 [9869716.001]
  • [Cites] Gastrointest Endosc. 1999 Feb;49(2):170-6 [9925694.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):543-8 [10029612.001]
  • [Cites] Gut. 2002 Dec;51(6):763-4 [12427769.001]
  • [Cites] Gut. 2002 Dec;51(6):776-80 [12427775.001]
  • [Cites] Gut. 2003 Jan;52(1):14-5 [12477751.001]
  • [Cites] J Clin Pathol. 1999 Jul;52(7):509-12 [10605403.001]
  • [Cites] J Photochem Photobiol B. 1999 Nov-Dec;53(1-3):75-80 [10672532.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2000 Jul;10(3):421-37 [10899256.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1102-5 [10931058.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):328-32 [10968845.001]
  • [Cites] Gut. 2000 Nov;47(5):612-7 [11034574.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):343-50 [11147906.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Feb;13(2):97-9 [11246628.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):257-61 [11293760.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1357-62 [11578292.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Gastrointest Endosc. 2003 Jun;57(7):854-9 [12776032.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):183-8 [12872083.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):449-55, vi [14629101.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):457-66 [14629102.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):467-81 [14629103.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):491-504 [14629105.001]
  • (PMID = 15888799.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 84
  • [Other-IDs] NLM/ PMC1774518
  •  go-up   go-down


10. Avilés A, Reymunde A, Santiago N: Balloon-based electrode for the ablation of non-dysplastic Barrett's esophagus: ablation of intestinal metaplasia (AIM II Trial). Bol Asoc Med P R; 2006 Oct-Dec;98(4):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balloon-based electrode for the ablation of non-dysplastic Barrett's esophagus: ablation of intestinal metaplasia (AIM II Trial).
  • INTRODUCTION: Barrett's esophagus (BE) is a condition in which an abnormal intestinal-type epithelium called specialized intestinal metaplasia (SIM) replaces the stratified squamous epithelium that normally lines the distal esophagus.
  • This intestinal metaplasia predisposes patients to esophageal adenocarcinoma, the most rapidly rising tumor incidence over the last 30 years, with an annual incidence of 0.5% in patients with BE and a survival rate less than 10% in 5 years.
  • The objective of the study was to assess the safety and efficacy of circumferential endoscopic ablation of Barrett's esophagus using the HALO360 System.
  • METHODS: Patients with non-dysplastic Barrett's esophagus confirmed within the previous year were treated twice per session with a balloon-based, bipolar radiofrequency ablation device with a pre selected energy of 10 J/ cm2 at 260 W for 10 secs, achieving full thickness ablation of epithelium followed by Omeprazole 40 mg PO BID for 1 month and then, daily.
  • CONCLUSIONS: In spite of the multiple treatment options for BE, especially among ablation techniques, radiofrequency ablation therapy is achieving promising results with a full thickness ablation of Barrett's epithelium in 76.2% of patients without direct injury to the submucosa, avoiding formation of strictures and minimal side effects from treatment.
  • [MeSH-major] Barrett Esophagus / surgery. Catheter Ablation / instrumentation. Catheterization / instrumentation

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19610568.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Puerto Rico
  •  go-up   go-down


11. De Gottardi A, Dumonceau JM, Bruttin F, Vonlaufen A, Morard I, Spahr L, Rubbia-Brandt L, Frossard JL, Dinjens WN, Rabinovitch PS, Hadengue A: Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer; 2006;5:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
  • BACKGROUND: Barrett's esophagus, a risk factor for esophageal adenocarcinoma, is associated with reflux disease.
  • The aim of this study was to assess the expression of bile acid receptors in the esophagus (normal, esophagitis, Barrett's esophagus and adenocarcinoma) and to investigate their possible function.
  • RESULTS: the expression of the bile acid receptors FXR and VDR in esophageal biopsies from patients with a normal mucosa, esophagitis, Barrett's esophagus or adenocarcinoma (n = 6 per group) and in cell lines derived from Barrett's esophagus and esophageal adenocarcinoma, was assessed by real time Q-PCR and immunohistochemistry.
  • The effect of guggulsterone, an antagonist of bile acid receptors, on apoptosis of Barrett's esophagus-derived cells was assessed morphologically, by flow cytometry and by measuring caspase 3 activity.
  • The expression of FXR was increased in esophagitis, Barrett's esophagus and adenocarcinoma compared to normal mucosa by a mean of 44, 84 and 16, respectively.
  • Immunohistochemistry showed a weak expression in normal esophagus, a strong focal reactivity in Barrett's esophagus, and was negative in adenocarcinoma.
  • In cell cultures, the expression of FXR was high in Barrett's esophagus-derived cells and almost undetectable in adenocarcinoma-derived cells, whereas VDR expression in these cell lines was not significantly different.
  • CONCLUSION: the bile acid receptor FXR is significantly overexpressed in Barrett's esophagus compared to normal mucosa, esophagitis and esophageal adenocarcinoma.
  • The induction of apoptosis by guggulsterone in a Barrett's esophagus-derived cell line suggests that FXR may contribute to the regulation of apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Barrett Esophagus / metabolism. DNA-Binding Proteins / metabolism. Pregnenediones / pharmacology. Receptors, Cytoplasmic and Nuclear / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Biopsy. Cell Culture Techniques. Cell Line, Tumor. Esophageal Neoplasms / metabolism. Esophagitis, Peptic / metabolism. Female. Gene Expression / drug effects. Gene Expression Regulation, Neoplastic. HT29 Cells. Humans. Immunohistochemistry. Male. Middle Aged. Precancerous Conditions / metabolism. Receptors, Calcitriol / agonists. Receptors, Calcitriol / antagonists & inhibitors. Receptors, Calcitriol / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:459-81 [11031244.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):662-87 [15798098.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1246-50 [11350890.001]
  • [Cites] Virchows Arch. 2001 May;438(5):451-6 [11407472.001]
  • [Cites] Science. 2002 May 17;296(5571):1313-6 [12016314.001]
  • [Cites] Science. 2002 May 31;296(5573):1703-6 [11988537.001]
  • [Cites] Gene. 2002 May 15;290(1-2):35-43 [12062799.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):686-92 [12196918.001]
  • [Cites] Lancet. 2002 Nov 16;360(9345):1587-9 [12443613.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1183-90 [12807723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3668-73 [14990788.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):57-67 [15213619.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):982-9 [15309887.001]
  • [Cites] Ann Thorac Surg. 1993 Jun;55(6):1386-92; discussion 1392-3 [8512386.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1897-907 [7768397.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2244-51 [8630384.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Arch Surg. 1997 Jul;132(7):728-33 [9230856.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Science. 1999 May 21;284(5418):1362-5 [10334992.001]
  • [Cites] Arch Biochem Biophys. 1999 Aug 1;368(1):14-22 [10415106.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47148-58 [15322087.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):424-31 [15667503.001]
  • [Cites] Mol Pharmacol. 2005 Mar;67(3):948-54 [15602004.001]
  • [Cites] Curr Pharm Des. 2001 Mar;7(4):231-59 [11254888.001]
  • (PMID = 17054793.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Pregnenediones; 0 / Receptors, Calcitriol; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Transcription Factors; 0 / farnesoid X-activated receptor; A4PW148END / pregna-4,17-diene-3,16-dione
  • [Other-IDs] NLM/ PMC1624849
  •  go-up   go-down


12. Lagergren J: Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol; 2006;20(5):803-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?
  • The rapid increase in the incidence of oesophageal adenocarcinoma, particularly among white males, seems to be a true increase occurring in many parts of the industrialised world during the last few decades.
  • Barrett's oesophagus, gastrooesophageal reflux, high body mass, male sex, tobacco smoking, and high dietary intake of fruit and vegetables.
  • Other factors have been found to be possibly inversely linked with the risk of oesophageal adenocarcinoma, including infection with Helicobacter pylori and anti-inflammatory drugs (such as aspirin and other non-steroidal anti-inflammatory drugs, including cyclo-oxygenase inhibitors).
  • The methodological problem of 'confounding by indication' makes it difficult to interpret the results of anti-inflammatory drugs, and currently such medication cannot be recommended for the prevention of oesophageal adenocarcinoma.
  • Similarly, since there is no strong evidence of a preventive effect of medical or surgical antireflux therapy with regard to risk of oesophageal adenocarcinoma, such therapy cannot be recommended in the prevention of this cancer.
  • Although some of the known risk factors might contribute to the increasing incidence of oesophageal adenocarcinoma, the explanation that can entirely explain this striking trend remains to be identified.
  • Oesophageal adenocarcinoma is a highly deadly cancer, but the overall prognosis and the prognosis after oesophageal cancer surgery has improved during recent years.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control
  • [MeSH-minor] Age Factors. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Barrett Esophagus / complications. Body Mass Index. Chemoprevention. Esophageal Sphincter, Lower / drug effects. Food Habits. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / therapy. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Prognosis. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997162.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Number-of-references] 69
  •  go-up   go-down


13. Prasad GA, Bansal A, Sharma P, Wang KK: Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol; 2010 Jul;105(7):1490-1502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of progression in Barrett's esophagus: current knowledge and future directions.
  • Barrett's esophagus (BE) is the strongest risk factor for esophageal adenocarcinoma (EAC), a malignancy with persistently poor long-term outcomes.
  • [MeSH-major] Barrett Esophagus / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aneuploidy. Biomarkers / analysis. Disease Progression. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Female. Humans. Loss of Heterozygosity. Male. Predictive Value of Tests. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4780-8 [15107828.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):280-4 [15278064.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):920-4 [15309878.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1657-66 [15330898.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1233-8 [15481000.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Gut. 1980 Jan;21(1):26-31 [7364315.001]
  • [Cites] Eur J Surg Oncol. 2005 Sep;31(7):755-9 [15979837.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 1;22(9):759-68 [16225483.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):682-5 [16246679.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3383-7 [11151865.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1286-93 [11729107.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):114-8 [16330950.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] World J Gastroenterol. 2005 Nov 21;11(43):6807-14 [16425388.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):439-43 [16437272.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):260-7 [16645214.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3084-92 [16407829.001]
  • [Cites] Ann Intern Med. 2006 Jun 20;144(12):945-8 [16785487.001]
  • [Cites] BMJ. 2006 Jun 24;332(7556):1512 [16793832.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1421-9 [16863542.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Diagn Mol Pathol. 2006 Sep;15(3):125-30 [16932066.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):214-7 [16957739.001]
  • [Cites] Nature. 2006 Sep 14;443(7108):159 [16971940.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):668-74 [17211862.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):494-6 [17335444.001]
  • [Cites] Am J Gastroenterol. 1999 Dec;94(12):3420-6 [10606297.001]
  • [Cites] Ann Intern Med. 2000 Apr 18;132(8):612-20 [10766679.001]
  • [Cites] Nutr Cancer. 2000;36(1):7-13 [10798210.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):27-31 [11808966.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1113-21 [11910361.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):29-35; discussion 36 [11986015.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1340-5 [12094847.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52 [12163328.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1930-6 [12190156.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2508-13 [12385431.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):291-8 [12616111.001]
  • [Cites] Gut. 2003 Apr;52(4):486-9 [12631655.001]
  • [Cites] Dis Esophagus. 2003;16(2):83-9 [12823203.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2390-4 [14638338.001]
  • [Cites] Med J Aust. 2004 Apr 19;180(8):387-91 [15089728.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] Cancer Lett. 2007 Jun 28;251(2):278-87 [17321043.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2087-102 [17498505.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):11-21 [17592284.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):581-7 [17611911.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):643-6 [17611920.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1137-44 [17640552.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):403-11 [17681161.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):394-8 [18045592.001]
  • [Cites] Genes Chromosomes Cancer. 2008 May;47(5):396-404 [18265409.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):604-9 [18155214.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Nutr Cancer. 2008;60(1):39-48 [18444134.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1263-73 [18477350.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1380-5 [18559552.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):24-31 [18442484.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7987-91 [11753681.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(4):741-50 [18656827.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Gastroenterology. 2008 Aug;135(2):370-9 [18538141.001]
  • [Cites] Gut. 2008 Sep;57(9):1207-13 [18469091.001]
  • [Cites] Adv Anat Pathol. 2008 Sep;15(5):279-86 [18724101.001]
  • [Cites] Am J Gastroenterol. 2008 Sep;103(9):2333-40; quiz 2341 [18671819.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jan;7(1):27-32 [18986846.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] J Mol Diagn. 2009 Mar;11(2):148-54 [19179455.001]
  • [Cites] Lab Invest. 2009 Apr;89(4):385-97 [18663352.001]
  • [Cites] Am J Gastroenterol. 2009 May;104(5):1093-6 [19417749.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jun;7(6):653-8; quiz 606 [19264576.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Dig Dis Sci. 1989 Sep;34(9):1336-9 [2766899.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1050-3 [1422717.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):119-29 [8514029.001]
  • [Cites] Gut. 1993 Jun;34(6):727-31 [8314502.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1155-8 [8339208.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):1961-4 [8616831.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Am J Gastroenterol. 1996 Nov;91(11):2310-3 [8931408.001]
  • [Cites] Am J Gastroenterol. 1997 Mar;92(3):407-13 [9068459.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):697-701 [9125634.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):751-60 [15720801.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):927-35 [15784042.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):49-54 [15973101.001]
  • [Cites] Ann Intern Med. 2005 Aug 2;143(3):199-211 [16061918.001]
  • (PMID = 20104216.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA135991; United States / NCI NIH HHS / CA / R03 CA135991-01; United States / NCI NIH HHS / CA / R03 CA135991-02; United States / NCI NIH HHS / CA / R03CA 135991-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 143
  • [Other-IDs] NLM/ NIHMS216204; NLM/ PMC3408387
  •  go-up   go-down


14. DeMeester SR: New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg; 2008 Feb;85(2):S747-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Endoscopy / methods. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222209.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 25
  •  go-up   go-down


15. Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, Nachbar L, Huijsmans J, Vieth M, Stolte M: Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc; 2007 Jan;65(1):3-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer).
  • BACKGROUND: In view of the increasing incidence of adenocarcinoma in Barrett's esophagus and the mortality and high morbidity rates associated with surgical therapy for this condition, safe and effective but less invasive methods of treatment are needed.
  • PATIENTS: A total of 100 consecutive patients (mean age, 62.1 +/- 10.9 years; range, 31-86 years) with low-risk adenocarcinoma of the esophagus (macroscopic types I, IIa, IIb, and IIc; lesion diameter up to 20 mm; mucosal lesion without invasion into lymph vessels and veins; and histologic grades G1 and G2) arising in Barrett's metaplasia.
  • CONCLUSIONS: Endoscopic resection is associated with favorable outcomes for low-risk patients with early esophageal adenocarcinoma (Barrett's carcinoma).
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Endoscopy, Gastrointestinal. Esophageal Neoplasms / surgery


16. Li YM, Li L, Yu CH, Liu YS, Xu CF: A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci; 2008 Nov;53(11):2837-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review and meta-analysis of the treatment for Barrett's esophagus.
  • As evidence-based strategies to the clinical management of Barrett's esophagus (BE) are lacking, we have carried out a systematic review and meta-analysis of all published randomized controlled trials with the aim of evaluating the value of different approaches in the treatment of BE.
  • The pharmacological therapy, antireflux surgery, and endoscopic ablative techniques are promising in terms of treating BE, but the studies carried out to date have had no adequate power to assess the effect of treatment on reducing and preventing progression to adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):750-8 [16118910.001]
  • [Cites] Gastrointest Endosc. 2004 Jan;59(1):1-7 [14722539.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):554-8 [11323578.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1289-96 [15606390.001]
  • [Cites] Dis Esophagus. 2006;19(5):335-9 [16984528.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):1016-20 [18043104.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):760-9 [14595320.001]
  • [Cites] Lasers Surg Med. 2002;31(5):299-304 [12430146.001]
  • [Cites] Gut. 2004 Jun;53(6):785-90 [15138203.001]
  • [Cites] Gut. 1999 Oct;45(4):489-94 [10486353.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Gut. 2000 Nov;47(5):612-7 [11034574.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Gut. 2006 Sep;55(9):1233-9 [16905695.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] J Pathol. 2005 Jan;205(1):57-64 [15586364.001]
  • [Cites] Endoscopy. 2003 Jun;35(6):496-501 [12783347.001]
  • [Cites] Gut. 2000 Apr;46(4):574-7 [10716690.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):159-64 [10425406.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):232-40 [15729231.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):40-4 [9445108.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):506-14 [15812401.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1357-62 [11578292.001]
  • [Cites] Ann Intern Med. 2001 Dec 4;135(11):982-9 [11730399.001]
  • [Cites] JAMA. 2001 May 9;285(18):2331-8 [11343480.001]
  • [Cites] Dis Esophagus. 2004;17(3):243-6 [15361098.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):291-8 [12616111.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1762-9 [16817835.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gut. 2001 Apr;48(4):580-1 [11288739.001]
  • (PMID = 18427992.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Number-of-references] 34
  •  go-up   go-down


17. Switzer-Taylor V, Schlup M, Lübcke R, Livingstone V, Schultz M: Barrett's esophagus: a retrospective analysis of 13 years surveillance. J Gastroenterol Hepatol; 2008 Sep;23(9):1362-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus: a retrospective analysis of 13 years surveillance.
  • BACKGROUND AND AIMS: The incidence of esophageal adenocarcinoma has increased significantly.
  • Barrett's esophagus (BE), a known precursor, has a high prevalence but only few patients with this condition progress to malignancy--surveillance and screening programs are controversial and lack proven efficacy.
  • METHODS: Data from patients with histologically proven Barrett's esophagus (1992-2003) that participated in a surveillance program were identified and analyzed retrospectively until 2005.
  • RESULTS: 404/536 patients had Barrett's esophagus confirmed histologically of which 212 (53%) were followed in a surveillance program (mean 3.95 years per patient).
  • Histologically, Barrett's mucosa was seen in 54%, low-grade dysplasia in 18%, ulcerations in 9%, high-grade dysplasia in 2%.
  • CONCLUSION: During 13 years of Barrett's surveillance, 88% of all adenocarcinoma occurred in a subset of only 11% patients.
  • To stratify surveillance for Barrett's esophagus, programs could focus on male patients with dysplasia or ulcerations on index endoscopy.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Esophagus / pathology. Mass Screening. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2008 Sep;23(9):1311-2 [18853989.001]
  • (PMID = 18205769.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


18. Casson AG, Zheng Z, Evans SC, Veugelers PJ, Porter GA, Guernsey DL: Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis; 2005 Sep;26(9):1536-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.
  • To test the hypothesis that aberrations of DNA repair contribute to susceptibility for the progression of gastroesophageal reflux disease (GERD) into Barrett esophagus (BE) and esophageal adenocarcinoma (EADC), we studied the frequency of polymorphisms of selected DNA repair genes in patients with GERD (n = 126), BE (n = 125) and EADC (n = 56) enrolled in a 2-year prospective case-control study.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. DNA Repair / genetics. Esophageal Neoplasms / genetics. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878910.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3
  •  go-up   go-down


19. Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE, Sarbia M: Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol; 2005 Dec;131(12):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using PCR based restriction fragment length polymorphism and single strand conformational polymorphism, we determined single nucleotide exchanges in the p16 and cyclin D1 genes among 56 esophageal adenocarcinomas (ADC) arising in Barrett's esophagus, 95 cardiac gastric ADC, and in 191 distal gastric ADC.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Esophageal Neoplasms / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine. Barrett Esophagus / complications. Cardia. Case-Control Studies. Cysteine. DNA, Neoplasm / analysis. Female. Gene Frequency. Glycine. Homozygote. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Polymorphism, Single Nucleotide. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1195-9 [11470749.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):176 [12582032.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):404-14 [10862049.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):640-5 [12101111.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):1005-11 [7675441.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):476-86 [15297940.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1499-503 [12807740.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):98-103 [12532425.001]
  • [Cites] Int J Cancer. 2004 Mar;109(1):138-43 [14735480.001]
  • [Cites] Int J Cancer. 1998 Jan 19;75(2):193-8 [9462707.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Urology. 2004 Jul;64(1):74-8 [15245939.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1007-10 [11490786.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):281-4 [12673692.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77 [9823374.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1405 [12151361.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2843-8 [14657069.001]
  • (PMID = 16163549.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 136601-57-5 / Cyclin D1; K848JZ4886 / Cysteine; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


20. Islami F, Kamangar F, Boffetta P: Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions. Am J Gastroenterol; 2009 Oct;104(10):2646-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions.
  • [MeSH-major] Adenocarcinoma / chemically induced. Barrett Esophagus / chemically induced. Esophageal Neoplasms / chemically induced. Proton Pump Inhibitors / adverse effects

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806109.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Letter; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  • [Number-of-references] 6
  •  go-up   go-down


21. Kinoshita Y, Yuki T: [Medical treatment of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medical treatment of Barrett's esophagus].
  • In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis.
  • The values of PPI and aspirin/NSAIDs for the prevention of Barrett's carcinoma are still under investigation all over the world.
  • Since many groups are actively working to find the appropriate methods for preventing carcinogenesis on the Barrett's esophagus, we will have an evidence-based strategy for the prevention of Barrett's adenocarcinoma in near future.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Barrett Esophagus / drug therapy. Cyclooxygenase Inhibitors / therapeutic use. Enzyme Inhibitors / therapeutic use
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Animals. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Drug Therapy, Combination. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / drug therapy. Humans. Membrane Proteins. Prostaglandin-Endoperoxide Synthases / physiology. Proton Pump Inhibitors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101238.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Enzyme Inhibitors; 0 / Membrane Proteins; 0 / Proton Pump Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; R16CO5Y76E / Aspirin
  • [Number-of-references] 24
  •  go-up   go-down


22. Castilloux J, Bouron-Dal Soglio D, Faure C: Endoscopic assessment of children with esophageal atresia: Lack of relationship of esophagitis and esophageal metaplasia to symptomatology. Can J Gastroenterol; 2010 May;24(5):312-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Late complications of esophageal atresia (EA), particularly esophagitis and Barrett's esophagus, are increasingly being recognized.
  • No intestinal metaplasia or adenocarcinoma was detected.

  • Genetic Alliance. consumer health - Esophageal Atresia.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Gastroenterol Nutr. 2001;32 Suppl 2:S1-31 [11525610.001]
  • [Cites] J Paediatr Child Health. 1997 Oct;33(5):388-93 [9401880.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] J Pediatr Surg. 2003 May;38(5):702-4 [12720174.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):210-5 [15699699.001]
  • [Cites] J Pediatr Surg. 2005 Apr;40(4):719-20 [15852288.001]
  • [Cites] J Pediatr Surg. 2005 Aug;40(8):1227-31 [16080923.001]
  • [Cites] J Pediatr Surg. 2005 Dec;40(12):e1-4 [16338286.001]
  • [Cites] J Pediatr Surg. 2006 Feb;41(2):331-4 [16481246.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Dis Esophagus. 2006;19(5):366-72 [16984534.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] J Pediatr Surg. 1998 Sep;33(9):1341-6 [9766349.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):2825-8 [10520828.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1392-9 [17101315.001]
  • [Cites] J Pediatr Surg. 2007 Feb;42(2):370-4 [17270551.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jun;5(6):702-6 [17544997.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Pediatr Surg Int. 2008 May;24(5):531-6 [18351365.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):102-6 [18607277.001]
  • [Cites] Pediatr Surg Int. 2003 Apr;19(1-2):40-3 [12721721.001]
  • [Cites] Ann Surg. 2003 Nov;238(5):686-9 [14578730.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):661-70 [14595298.001]
  • [Cites] Pediatr Surg Int. 2004 Jun;20(6):402-7 [15148615.001]
  • [Cites] Chest. 2004 Sep;126(3):915-25 [15364774.001]
  • [Cites] J Pediatr Surg. 1989 Aug;24(8):741-4 [2769539.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1178-80 [8308687.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1208-11 [7807346.001]
  • [Cites] Arch Surg. 1995 May;130(5):502-8; discussion 508-9 [7748088.001]
  • [Cites] Am J Gastroenterol. 1997 Jan;92(1):27-31 [8995932.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Am J Gastroenterol. 1997 Aug;92(8):1293-7 [9260792.001]
  • [Cites] J Pediatr Surg. 1997 Nov;32(11):1570-4 [9396528.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • (PMID = 20485706.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2886573
  •  go-up   go-down


23. Groome M, Lindsay J, Ross PE, Cotton JP, Hupp TR, Dillon JF: Use of oesophageal stress response proteins as potential biomarkers in the screening for Barrett's oesophagus. Eur J Gastroenterol Hepatol; 2008 Oct;20(10):961-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of oesophageal stress response proteins as potential biomarkers in the screening for Barrett's oesophagus.
  • INTRODUCTION: Oesophageal adenocarcinoma is an increasingly common diagnosis and cause of death; risk factors include 'Barrett's epithelium' (BE).
  • [MeSH-major] Barrett Esophagus / diagnosis. Heat-Shock Proteins / blood. Precancerous Conditions / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787461.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CRNN protein, human; 0 / HSP70 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / SEP70 protein, human; EC 5.3.4.1 / AGR2 protein, human
  •  go-up   go-down


24. Huang Q, Yu C, Zhang X, Goyal RK: Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. BMC Clin Pathol; 2008 May 30;8:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma.
  • BACKGROUND: The purpose of this study was to compare DNA histograms obtained by standard flow cytometry (FC) and high fidelity image cytometry on sections (ICS) in normal gastrointestinal mucosa and Barrett's adenocarcinoma (BAC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):787-95 [10505041.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Jun;22(3):199-205 [10872035.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3164-70 [11306503.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Onkologie. 2003 Feb;26(1):32-7 [12624515.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97 [12916666.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):904-9 [14871819.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1887-94 [15447746.001]
  • [Cites] Histopathology. 2004 Oct;45(4):312-34 [15469470.001]
  • [Cites] BMC Clin Pathol. 2005 Aug 12;5:7 [16095543.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):649-55 [17557867.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(10):703-10 [1816011.001]
  • [Cites] Gastroenterology. 1991 Dec;101(6):1588-93 [1955124.001]
  • [Cites] Cytometry. 1990;11(3):431-7 [2340777.001]
  • [Cites] Ann Pathol. 1990;10(3):161-5 [2386598.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):518-27 [2470665.001]
  • [Cites] Semin Diagn Pathol. 1989 Feb;6(1):55-82 [2645625.001]
  • [Cites] Cytometry. 1989 May;10(3):326-33 [2714115.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Jun;17(3):163-71 [7546050.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Mod Pathol. 1994 Aug;7(6):652-64 [7991524.001]
  • [Cites] Mod Pathol. 1993 May;6(3):270-5 [8346174.001]
  • [Cites] Cytometry. 1993;14(5):472-7 [8354117.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):119-29 [8514029.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):553-60 [8666364.001]
  • [Cites] Anal Cell Pathol. 1996 Aug;11(3):159-71 [8888952.001]
  • [Cites] J Clin Pathol. 1996 Nov;49(11):931-7 [8944615.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Jun;20(3):178-86 [9642444.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • (PMID = 18513411.001).
  • [ISSN] 1472-6890
  • [Journal-full-title] BMC clinical pathology
  • [ISO-abbreviation] BMC Clin Pathol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062867
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2424056
  •  go-up   go-down


25. Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D: Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol; 2009 Aug;9(4):396-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of esophageal adenocarcinoma is increasing largely in Western populations, and patients diagnosed with this cancer continue to have a poor prognosis.
  • The major risk factors are gastroesophageal reflux disease and Barrett's esophagus, both of which are associated with inflammation of the esophageal squamous epithelium, a condition called reflux esophagitis.
  • The chronic inflammation that is present in Barrett's esophagus creates an environment suitable for DNA damage and altered expression of genes involved in cellular proliferation and inhibition of apoptosis.
  • [MeSH-major] Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Inflammation Mediators / physiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596608.001).
  • [ISSN] 1471-4973
  • [Journal-full-title] Current opinion in pharmacology
  • [ISO-abbreviation] Curr Opin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Inflammation Mediators
  • [Number-of-references] 63
  •  go-up   go-down


26. Clément G, Guilleret I, He B, Yagui-Beltrán A, Lin YC, You L, Xu Z, Shi Y, Okamoto J, Benhattar J, Jablons D: Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci; 2008 Jan;99(1):46-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
  • The role of Wnt antagonists in the carcinogenesis of esophageal adenocarcinoma (EAC) remains unclear.
  • We hypothesized that downregulation of the Wnt inhibitory factor-1 (WIF-1) might be involved in the neoplastic progression of Barrett's esophagus (BE).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005197.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-03; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA 093708-01A3; United States / NCI NIH HHS / CA / R01 CA093708-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents; 0 / Repressor Proteins; 0 / WIF1 protein, human; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Chiba N, Yoshioka T, Sakayori M, Mikami Y, Miyazaki S, Akiyama S, Otsuka K, Yamaura G, Shibata H, Kato S, Kato S, Ishioka C: AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report. Anticancer Res; 2005 Jul-Aug;25(4):2965-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report.
  • A case of alpha-fetoprotein (AFP)-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastases, responding to chemotherapy, is reported.
  • A 47-year-old man was admitted to our hospital with abdominal pain after subtotal esophagectomy for an esophageal adenocarcinoma in association with Barrett's esophagus, and was diagnosed as having multiple liver tumors.
  • Since microscopic examination of the resected tumor showed a poorly-differentiated adenocarcinoma with hepatoid features displaying AFP-immunoreactivity, the liver tumors were thus considered to be metastatic deposits.
  • This is the first report, to our knowledge, of effective chemotherapy for liver metastases from an AFP-producing hepatoid adenocarcinoma of the esophagus.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Barrett Esophagus / drug therapy. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res. 2006 Jul-Aug;26(4b):3203. Yoshiki, Mikami [corrected to Mikami, Yoshiki]
  • (PMID = 16080552.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Lopes CV, Pereira-Lima JC, Hartmann AA, Tonelotto E, Salgado K: [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?]. Arq Gastroenterol; 2005 Oct-Dec;42(4):233-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?].
  • [Transliterated title] O critério de positividade para a análise imunoistoquímica da p53 na confirmação da displasia do esôfago de Barrett faz diferença?
  • BACKGROUND: Barrett's esophagus is the most serious complication of the gastroesophageal reflux disease and presents a malignant potential.
  • The expression of the tumoral marker p53 increases with the dysplasia-adenocarcinoma sequence.
  • AIMS: To evaluate the p53 expression in Barrett's esophagus with or without dysplasia according to the two positive immunostaining criteria.
  • MATERIALS AND METHODS: The material was constituted by endoscopic biopsy specimens from 42 patients with Barrett's esophagus.
  • According to the two different p53 immunostaining criteria, the protein was detected in non-dysplastic Barrett's metaplasia, respectively, in 5 (13.9%) and 14 (38.9%) patients.
  • CONCLUSIONS: In this group, p53 immunohistochemical expression, regardless of positive criteria take into account, was not useful for detecting dysplasia in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / pathology. Precancerous Conditions / pathology. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444378.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor SL, Grace MG, Depot M, International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus: Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc; 2005 Oct;62(4):488-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.
  • BACKGROUND: Barrett's esophagus (BE) may lead to high-grade dysplasia (HGD) and adenocarcinoma.
  • The objective was to examine the impact of treating patients with BE and with HGD by using porfimer sodium (POR) and photodynamic therapy (PDT) for ablating HGD and reducing the incidence of esophageal adenocarcinoma.
  • The occurrence of adenocarcinoma in the PORPDT group (13%) (n=18) was significantly lower (p < 0.006) compared with the OM group (28%) [corrected] (n=20).
  • CONCLUSIONS: PORPDT in conjunction with omeprazole is an effective therapy for ablating HGD in patients with BE and in reducing the incidence of esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / drug therapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Precancerous Conditions / drug therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Aged. Biopsy. Disease Progression. Esophageal Neoplasms / pathology. Esophageal Neoplasms / prevention & control. Esophagoscopy. Female. Follow-Up Studies. Humans. International Cooperation. Male. Prospective Studies. Treatment Outcome


30. Zhang X, Huang Q, Goyal RK, Odze RD: DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions. Am J Surg Pathol; 2008 Sep;32(9):1327-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions.
  • The purpose of this study was to define the zonal DNA content distribution in the basal versus the superficial crypt cells in Barrett's esophagus (BE) and related neoplastic lesions.
  • In full crypts, compared with gastric controls, the prevalence of DNA aneuploidy increased significantly (P<0.01) from nondysplastic BE to basal crypt dysplasia (BCD), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and adenocarcinoma (AC).
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. DNA / analysis. Esophageal Neoplasms / genetics. Ploidies. Precancerous Conditions / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670357.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK62687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


31. Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A, Tanière P, Chariot A, Scoazec JY, de Moura Gallo CV, Merville MP, Hainaut P: Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene; 2006 Sep 21;25(42):5708-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In esophageal cancer, there was a correlation between Cox-2 expression and wild-type TP53 in Barrett's esophagus (BE) and in adenocarcinoma, but not in squamous cell carcinoma (P<0.01).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682957.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / NF-kappa B; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.22.- / Caspases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


32. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ: Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer; 2008 Nov 15;123(10):2331-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the CDH13 gene has been shown to undergo epigenetic silencing by promoter methylation in many types of tumors, hypermethylation of this gene in Barrett's-associated esophageal adenocarcinogenesis has not been studied.
  • CDH13 hypermethylation showed discriminative receiver-operator characteristic curve profiles, sharply demarcating esophageal adenocarcinoma (EAC) from esophageal squamous cell carcinoma (ESCC) and normal esophagus (NE) (p < 0.0001).
  • CDH13 normalized methylation values (NMV) were significantly higher in Barrett's esophagus (BE), dysplastic BE (D) and EAC than in NE (p < 0.0000001).
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. DNA Methylation. Esophageal Neoplasms / genetics. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18729198.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA001808; United States / NCI NIH HHS / CA / CA085069; United States / NCI NIH HHS / CA / CA106763
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA Primers; 0 / H-cadherin; M801H13NRU / Azacitidine
  •  go-up   go-down


33. Paterson AL, Fitzgerald RC: Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma. Expert Opin Med Diagn; 2007 Nov;1(3):363-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.
  • Barrett's oesophagus is a well-recognised premalignant lesion for oesophageal adenocarcinoma.
  • The majority of Barrett's cases within the population are undiagnosed, consequently most cases of oesophageal adenocarcinoma arise de novo.
  • The incidence of oesophageal adenocarcinoma has increased by more than sixfold in the last 30 years.
  • However, most patients with Barrett's oesophagus will not develop oesophageal adenocarcinoma.
  • The major focus of biomarker research in Barrett's oesophagus is to find a marker that is able to identify patients at the highest risk of progressing to adenocarcinoma.
  • Other potential roles include increasing the sensitivity of minimally invasive screening tests to identify patients with Barrett's oesophagus and predicting which patients are most likely to benefit from chemoprevention and endoscopic therapies.
  • In established oesophageal adenocarcinoma, biomarkers would be able to individualise patient management by providing valuable information on patient prognosis and their suitability for novel targeted therapies.
  • This review aims to explore the potential roles of biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma, focusing on the most extensively studied candidates and future novel developments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23489356.001).
  • [ISSN] 1753-0059
  • [Journal-full-title] Expert opinion on medical diagnostics
  • [ISO-abbreviation] Expert Opin Med Diagn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Selaru FM, Wang S, Yin J, Schulmann K, Xu Y, Mori Y, Olaru AV, Sato F, Hamilton JP, Abraham JM, Schneider P, Greenwald BD, Brabender J, Meltzer SJ: Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. Bioinform Biol Insights; 2007;1:127-136
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma.
  • BACKGROUND AND AIMS: Because of the extremely low neoplastic progression rate in Barrett's esophagus, it is difficult to diagnose patients with concomitant adenocarcinoma early in their disease course.
  • If biomarkers existed in normal squamous esophageal epithelium to identify patients with concomitant esophageal adenocarcinoma, potential applications would be far-reaching.
  • The aim of the current study was to identify global gene expression patterns in normal esophageal epithelium capable of revealing simultaneous esophageal adenocarcinoma, even located remotely in the esophagus.
  • METHODS: Tissues comprised normal esophageal epithelia from 9 patients with esophageal adenocarcinoma, 8 patients lacking esophageal adenocarcinoma or Barrett's, and 6 patients with Barrett's esophagus alone. cDNA microarrays were performed, and pattern recognition in each of these subgroups was achieved using shrunken nearest centroid predictors.
  • RESULTS: Our method accurately discriminated normal esophageal epithelia of 8/8 patients without esophageal adenocarcinoma or Barrett's esophagus and of 6/6 patients with Barrett's esophagus alone from normal esophageal epithelia of 9/9 patients with Barrett's esophagus and concomitant esophageal adenocarcinoma.
  • Thus, based on their corresponding normal esophageal epithelia alone, our method accurately diagnosed patients who had concomitant esophageal adenocarcinoma.
  • CONCLUSIONS: These global gene expression patterns, along with individual genes culled from them, represent potential biomarkers for the early diagnosis of esophageal adenocarcinoma from normal esophageal epithelia.
  • Genes discovered in normal esophagus that are differentially expressed in patients with vs. without esophageal adenocarcinoma merit further pursuit in molecular genetic, functional, and therapeutic interventional studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425214.001).
  • [Journal-full-title] Bioinformatics and biology insights
  • [ISO-abbreviation] Bioinform Biol Insights
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA001808; United States / NCI NIH HHS / CA / CA001808-05; United States / NCI NIH HHS / CA / R01 CA095323; United States / NCI NIH HHS / CA / CA095323-13; United States / NCI NIH HHS / CA / R21 CA106763; United States / NCI NIH HHS / CA / CA106763-02; United States / NIDDK NIH HHS / DK / T32 DK067872; United States / NCI NIH HHS / CA / U01 CA085069; United States / NCI NIH HHS / CA / CA085069-07
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


35. Cooper BT, Chapman W, Neumann CS, Gearty JC: Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther; 2006 Mar 15;23(6):727-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
  • BACKGROUND: There is little evidence that treatment of patients with Barrett's oesophagus with proton pump inhibitors over periods up to 6 years results in major regression of Barrett's oesophagus.
  • AIM: To determine if longer periods of treatment with proton pump inhibitors lead to significant regression of Barrett's oesophagus, and to determine the incidence of oesophageal adenocarcinoma in the proton pump inhibitor-treated patients.
  • METHODS: We analysed prospectively-collected data on Barrett's oesophagus patients treated with proton pump inhibitors for 1-13 years.
  • RESULTS: 188 patients with Barrett's oesophagus and intestinal metaplasia, were treated for 1-13 years with a proton pump inhibitor (966 years of treatment; mean 5.1 years).
  • Six patients developed dysplasia and three males developed adenocarcinoma during treatment (cancer incidence 0.31%).
  • CONCLUSIONS: Proton-pump inhibitor treatment over 1-13 years does not shorten the Barrett's oesophagus segment but squamous islands appear in many patients.
  • The incidence of oesophageal adenocarcinoma was low in these proton pump inhibitor-treated patients compared with published series.
  • [MeSH-major] Barrett Esophagus / drug therapy. Enzyme Inhibitors / administration & dosage. Proton Pump Inhibitors
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Esophageal Diseases / chemically induced. Esophageal Diseases / pathology. Esophageal Neoplasms / chemically induced. Esophageal Neoplasms / pathology. Female. Humans. Lansoprazole. Long-Term Care. Male. Middle Aged. Omeprazole / administration & dosage. Omeprazole / analogs & derivatives. Prospective Studies. Sex Factors. Treatment Outcome

  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2006 Dec;3(12):658-9 [17130871.001]
  • (PMID = 16556174.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Enzyme Inhibitors; 0 / Proton Pump Inhibitors; 0K5C5T2QPG / Lansoprazole; KG60484QX9 / Omeprazole
  •  go-up   go-down


36. Szachnowicz S, Cecconello I, Iriya K, Marson AG, Takeda FR, Gama-Rodrigues JJ: Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background. Clinics (Sao Paulo); 2005 Apr;60(2):103-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
  • Barrett's esophagus is the substitution of squamous epithelium of the distal esophagus by columnar epithelium.
  • Intestinal metaplasia in Barrett's esophagus is considered to be the main risk factor for the development of adenocarcinoma.
  • Diffuse adenocarcinoma and Barrett's esophagus without intestinal metaplasia are rare, and reports on the subject are scarce.
  • PURPOSE AND METHOD: To estimate the prevalence of adenocarcinoma in 297 patients with Barrett's esophagus, during the period of 1990 to 2002, and in 13 patients undergoing surgery, to conduct detailed macroscopic and microscopic analysis, with performance of immunohistochemical tests for p53 and Ki67, correlating the type of tumor with its adjacent epithelium.
  • RESULTS: In our patients with Barrett's esophagus, there was a prevalence of 5.7% of adenocarcinoma.
  • The tumors developed only when the Barrett's esophagus segment was long (>3.0 cm).
  • The histological study revealed 2 patients (15.4%) with Barrett's esophagus adjacent to a tumor with gastric metaplasia without the presence of intestinal metaplasia.
  • CONCLUSION: Adenocarcinoma develops from mixed columnar epithelium, either intestinal or gastric, showing both the gastric and the intestinal patterns; thus, tumors can also grow in columnar epithelium without intestinal metaplasia.
  • Barrett's esophagus should be followed up for the possibility of progression to malignancy, especially when the segment is longer than 3 cm.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Ki-67 Antigen / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880245.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


37. Inadomi JM: Surveillance in Barrett's esophagus: a failed premise. Keio J Med; 2009 Mar;58(1):12-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance in Barrett's esophagus: a failed premise.
  • BACKGROUND: It is recommended that patients in whom Barrett's esophagus is diagnosed undergo surveillance endoscopy.
  • METHODS: Quantitative techniques were used to examine surveillance in patients with Barrett's esophagus.
  • A retrospective case-control study was performed to determine whether surveillance endoscopy prolonged survival in a cohort of U.S. veterans diagnosed with esophageal adenocarcinoma.
  • Cost-effectiveness analysis was employed to compare competing strategies of management for patients with Barrett's esophagus to determine whether surveillance strategies using alternative biomarkers could out-perform dysplasia based surveillance, and whether new techniques for eradicating Barrett's metaplasia would constitute cost-effective strategies.
  • RESULTS: Surveillance did not improve long-term survival among veterans diagnosed with esophageal adenocarcinoma.
  • Cost-effectiveness analysis revealed that while screening 50-year old Caucasian males with heartburn may be cost-effective, surveillance even at 5 year intervals among patients with Barrett's esophagus without dysplasia exceeded the threshold of cost-effective care.
  • CONCLUSIONS: Current recommendations for the management of patients with Barrett's esophagus are flawed.
  • [MeSH-major] Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / economics. Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Biomarkers, Tumor / metabolism. Humans. Practice Guidelines as Topic. Risk Factors


38. Saleh W, Duranceau A, Martin J, Noiseux N, Poirier C, Ferraro P: Rapid progression of Barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient. J Thorac Cardiovasc Surg; 2010 Jan;139(1):217-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of Barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Lung Transplantation


39. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, Moskaluk CA, El-Rifai W: Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia; 2005 Sep;7(9):854-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
  • Chronic gastroesophageal reflux disease is a known risk factor for Barrett's esophagus (BE), which induces oxidative mucosal damage.
  • In this study, we have investigated the mRNA and protein expression of GPx3, and explored promoter hypermethylation as an epigenetic mechanism for GPx3 gene inactivation during Barrett's carcinogenesis.
  • Quantitative real-time reverse transcription polymerase chain reaction on 42 Barrett's adenocarcinomas (BAs) revealed consistently reduced levels of GPx3 mRNA in 91% of tumor samples.
  • GPx3 promoter hypermethylation was detected in 62% of Barrett's metaplasia, 82% of dysplasia, and 88% of BA samples.
  • Immunohistochemical staining of GPx3 in matching tissue sections (normal, BE, Barrett's dysplasia, and BA) revealed strong immunostaining for GPx3 in normal esophageal and gastric tissues.
  • However, weak to absent GPx3 staining was observed in Barrett's dysplasia and adenocarcinoma samples where the promoter was hypermethylated.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 1999 Nov;27(9-10):951-65 [10569628.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Dis Esophagus. 2000;13(1):28-31 [11005328.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:189-200 [11506813.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):55-9 [11781280.001]
  • [Cites] Am J Gastroenterol. 2002 Jan;97(1):22-6 [11808965.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41254-8 [12185074.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1688-97 [12721243.001]
  • [Cites] FASEB J. 2003 Jul;17(10):1195-214 [12832285.001]
  • [Cites] Ann Intern Med. 1978 Jul;89(1):122-7 [208444.001]
  • [Cites] Science. 1985 Jan 25;227(4685):375-81 [2981433.001]
  • [Cites] Arch Biochem Biophys. 1987 Aug 1;256(2):677-86 [3619451.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Arch Biochem Biophys. 1991 May 1;286(2):330-6 [1897960.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Sep;9(9):881-5 [9355787.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1463-71 [9843785.001]
  • [Cites] Nutr Cancer. 1998;32(2):64-70 [9919613.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):81-5 [10076569.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Arch Biochem Biophys. 1993 Sep;305(2):541-5 [8373192.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29382-4 [7961915.001]
  • [Cites] Gut. 1995 Aug;37(2):168-73 [7557561.001]
  • [Cites] Am J Surg. 1995 Dec;170(6):552-6; discussion 556-7 [7491999.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2557-63 [8637913.001]
  • [Cites] Eur J Cancer. 1996 Jan;32A(1):30-8 [8695238.001]
  • [Cites] Dis Esophagus. 1997 Jan;10(1):29-32; discussion 33 [9079270.001]
  • [Cites] Exp Physiol. 1997 Mar;82(2):291-5 [9129943.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2619-22 [9205067.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • (PMID = 16229808.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.11.1.- / GPX3 protein, human; EC 1.11.1.9 / Glutathione Peroxidase
  • [Other-IDs] NLM/ PMC1501938
  •  go-up   go-down


40. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, Selaru FM, Hamilton JP, Yang J, Abraham JM, Mori Y, Meltzer SJ: The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology; 2009 May;136(5):1689-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Barrett's esophagus (BE) is a highly premalignant disease that predisposes to the development of esophageal adenocarcinoma (EAC); however, the involvement of microRNAs (miRs) in BE-EAC carcinogenic progression is not known.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2008 Mar 13;27(12):1788-93 [17891175.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):372-9 [18449891.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4123-32 [18519671.001]
  • [Cites] Nature. 2000 Feb 24;403(6772):901-6 [10706289.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1183-90 [12807723.001]
  • [Cites] Cell. 2004 Jan 23;116(2 Suppl):S93-6, 2 p following S96 [15055593.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3087-95 [15126345.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):415-7 [15221970.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1996;53:283-319 [8650306.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):384-95 [9430630.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1554-66 [15887151.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3980-5 [15899785.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1559-63 [16141072.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2101-3 [16344076.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):1090-8 [16247466.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Nat Genet. 2007 Nov;39(11):1384-9 [17965714.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2167-74 [18212054.001]
  • (PMID = 19422085.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA106763-02; United States / NCI NIH HHS / CA / R21 CA106763; United States / NCI NIH HHS / CA / CA084986-09; United States / NCI NIH HHS / CA / CA85069; United States / NCI NIH HHS / CA / CA085069-10; United States / NCI NIH HHS / CA / CA01808; United States / NCI NIH HHS / CA / U01 CA084986-09; United States / NCI NIH HHS / CA / CA085069-08; United States / NCI NIH HHS / CA / U01 CA085069-08; United States / NCI NIH HHS / CA / U01 CA085069-10; United States / NCI NIH HHS / CA / CA001808-05; United States / NCI NIH HHS / CA / CA106763-02; United States / NCI NIH HHS / CA / U01 CA085069; United States / NCI NIH HHS / CA / R01 CA001808-05; United States / NCI NIH HHS / CA / R01 CA001808; United States / NIDDK NIH HHS / DK / T32 DK067872; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Membrane Proteins; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins
  • [Other-IDs] NLM/ NIHMS96324; NLM/ PMC2887605
  •  go-up   go-down


41. Chait MM: Gastroesophageal reflux disease: Important considerations for the older patients. World J Gastrointest Endosc; 2010 Dec 16;2(12):388-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophageal complications include erosive esophagitis, esophageal stricture, Barrett's esophagus and adenocarcinoma of the esophagus.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S5-9 [19262546.001]
  • [Cites] Gut. 1987 Nov;28(11):1484-8 [3428675.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S17-20 [19262541.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):190-200 [15654800.001]
  • [Cites] JAMA. 1997 Aug 27;278(8):659-62 [9272898.001]
  • [Cites] J Am Geriatr Soc. 1992 Dec;40(12):1209-11 [1447435.001]
  • [Cites] Gastroenterol Clin North Am. 1990 Sep;19(3):609-16 [2228166.001]
  • [Cites] World J Gastrointest Endosc. 2010 May 16;2(5):147-54 [21160742.001]
  • [Cites] Am J Gastroenterol. 2006 Sep;101(9):2128-38 [16848807.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):431-7 [8042041.001]
  • [Cites] N Engl J Med. 1992 Mar 19;326(12):786-92 [1538721.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):672-5 [14991936.001]
  • [Cites] Gastrointest Endosc. 2002 Feb;55(2):149-56 [11818914.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8 Suppl):S15-22 [10950101.001]
  • [Cites] Gastroenterology. 2010 Aug;139(2):409-17 [20451523.001]
  • [Cites] Chest. 2009 Nov;136(5 Suppl):e30 [20162786.001]
  • [Cites] J Am Geriatr Soc. 1998 Dec;46(12):1534-7 [9848814.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1430-6 [15307855.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep 15;18(6):595-604 [12969086.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Jun;14(6):651-68 [10848649.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):368-73 [10685737.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Sep;7(9):953-9 [19375520.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26 [17142109.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):660-4 [14988819.001]
  • [Cites] Gut. 2003 Jan;52(1):34-9 [12477756.001]
  • [Cites] Arch Intern Med. 2001 Jan 8;161(1):45-52 [11146697.001]
  • [Cites] Age Ageing. 2000 Mar;29(2):125-30 [10791446.001]
  • [Cites] Ann Intern Med. 2010 Mar 16;152(6):337-45 [20231564.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2009 Jan;19(1):1-22, v [19232277.001]
  • [Cites] N Engl J Med. 2008 Oct 16;359(16):1700-7 [18923172.001]
  • [Cites] N Engl J Med. 2006 Jun 1;354(22):2340-8 [16738270.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):351-3 [9517638.001]
  • [Cites] Gastroenterology. 1982 Oct;83(4):889-95 [7106518.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1652-6 [15330897.001]
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):250-8 [12591037.001]
  • [Cites] Semin Gastrointest Dis. 1999 Jul;10(3):93-102 [10435696.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S26-32 [15324379.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1500-11 [11984534.001]
  • [Cites] Gastroenterology. 2010 Jul;139(1):7-13.e3 [20493864.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S10-6 [19262540.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Jun;8(3):202-7 [16764786.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Jan;20(1):26-9 [15610442.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct 1;20(7):751-60 [15379835.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1053-7 [7611195.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104 Suppl 2:S21-6 [19262543.001]
  • (PMID = 21191512.001).
  • [ISSN] 1948-5190
  • [Journal-full-title] World journal of gastrointestinal endoscopy
  • [ISO-abbreviation] World J Gastrointest Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3010469
  • [Keywords] NOTNLM ; Elderly / Gastroesophageal reflux disease / Older patient
  •  go-up   go-down


42. Fass R, Dickman R: Clinical consequences of silent gastroesophageal reflux disease. Curr Gastroenterol Rep; 2006 Jun;8(3):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Silent gastroesophageal reflux disease (GERD) is a very common phenomenon that involves the incidental finding of erosive esophagitis, Barrett's esophagus, and the evolution of esophageal adenocarcinoma in asymptomatic patients.
  • [MeSH-minor] Animals. Barrett Esophagus / diagnosis. Barrett Esophagus / epidemiology. Diagnosis, Differential. Endoscopy, Gastrointestinal. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / epidemiology. Humans. Incidence. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2005 May;127(5):1486-8 [15888817.001]
  • [Cites] Scand J Gastroenterol Suppl. 1993;199:18-21 [8171293.001]
  • [Cites] Digestion. 2000;62(2-3):82-6 [11025354.001]
  • [Cites] Semin Gastrointest Dis. 1996 Oct;7(4):169-84 [8902931.001]
  • [Cites] Gut. 1995 Jul;37(1):7-12 [7672684.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):296-300 [15067623.001]
  • [Cites] Am J Gastroenterol. 1993 Jan;88(1):11-9 [8420248.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):303-14 [11232668.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] Gut. 2001 Nov;49(5):624-8 [11600463.001]
  • [Cites] Gastroenterology. 1975 Aug;69(2):569-70 [1150059.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1448-56 [9136821.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):61-9 [8020690.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Dig Liver Dis. 2001 Jun-Jul;33(5):403-6 [11529651.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1200-5 [8898633.001]
  • [Cites] Gut. 2000 Dec;47 Suppl 4:iv69-72; discussion iv76 [11076922.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1353-62 [9834262.001]
  • [Cites] Dig Dis. 2004;22(2):100-7 [15383749.001]
  • [Cites] Dig Dis Sci. 1994 Feb;39(2):423-5 [8313828.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1363-73 [9834263.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):364-8 [2040529.001]
  • [Cites] J Pathol. 1979 Dec;129(4):161-7 [536881.001]
  • [Cites] Scand J Gastroenterol. 2005 Mar;40(3):275-85 [15932168.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gut. 1994 Apr;35(4):447-50 [8174979.001]
  • [Cites] Pharmacol Rev. 1999 Jun;51(2):159-212 [10353985.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Jul 15;22(2):79-94 [16011666.001]
  • [Cites] Gastrointest Endosc. 1986 Apr;32(2):78-80 [3710103.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Surg Gynecol Obstet. 1985 Dec;161(6):570-4 [4071370.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Sep;16(9):897-902 [15316415.001]
  • [Cites] Dig Dis Sci. 1993 Oct;38(10):1926-8 [8404416.001]
  • [Cites] Lancet. 2003 Feb 1;361(9355):385-91 [12573376.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] J Physiol. 1982 Nov;332:59-67 [6818340.001]
  • (PMID = 16764785.001).
  • [ISSN] 1522-8037
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


43. Kan T, Meltzer SJ: MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol; 2009 Dec;9(6):727-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
  • The molecular genetics of Barrett's esophagus (BE) and its evolution to esophageal adenocarcinoma (EAC) have been widely studied; however, the molecular mechanism of BE-EAC carcinogenesis has not been completely understood.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1559-63 [16141072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):2101-3 [16344076.001]
  • [Cites] Biol Pharm Bull. 2006 May;29(5):903-6 [16651716.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):803-12 [16997162.001]
  • [Cites] Nat Struct Mol Biol. 2006 Dec;13(12):1097-101 [17099701.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1479-86 [17110380.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2167-74 [18212054.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6667-78 [18663355.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8080-6 [19088023.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2189-204 [19120703.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Feb;10(2):126-39 [19165215.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):736-45 [19179615.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):850-61 [19269522.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2287-95 [19244118.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2195-200 [19276373.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):623-31 [19246618.001]
  • [Cites] Cell Res. 2009 Apr;19(4):439-48 [19238171.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1131-8 [19264914.001]
  • [Cites] BioDrugs. 2009;23(1):15-23 [19344188.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1940-8 [19342367.001]
  • [Cites] Keio J Med. 2009 Mar;58(1):12-8 [19398879.001]
  • [Cites] Hepatology. 2009 May;49(5):1595-601 [19296468.001]
  • [Cites] Gastroenterology. 2009 May;136(5):1689-700 [19422085.001]
  • [Cites] Mol Cancer Ther. 2009 May;8(5):1067-74 [19435867.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):26-33 [11781277.001]
  • [Cites] Oncogene. 2002 Jan 17;21(3):475-8 [11821959.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):415-7 [15221970.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Mayo Clin Proc. 1998 May;73(5):457-61 [9581588.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):235-40 [15531877.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • (PMID = 19773200.001).
  • [ISSN] 1471-4973
  • [Journal-full-title] Current opinion in pharmacology
  • [ISO-abbreviation] Curr Opin Pharmacol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA085069; United States / NCI NIH HHS / CA / CA077057-09; United States / NCI NIH HHS / CA / R01 CA077057-09; United States / NCI NIH HHS / CA / CA085069-10; United States / NCI NIH HHS / CA / CA146799; United States / NCI NIH HHS / CA / CA01808; United States / NCI NIH HHS / CA / U01 CA085069-10; United States / NCI NIH HHS / CA / R01 CA077057; United States / NCI NIH HHS / CA / U01 CA085069; United States / NCI NIH HHS / CA / R01 CA146799; United States / NCI NIH HHS / CA / R01 CA001808
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Number-of-references] 46
  • [Other-IDs] NLM/ NIHMS147315; NLM/ PMC2794797
  •  go-up   go-down


44. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG, Chang AC: Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res; 2010 Apr 1;16(7):2009-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity.
  • Because selenium-binding protein 1 (SELENBP1, SBP1, hSP56) has been shown to bind selenium covalently and selenium deficiency has been associated with esophageal adenocarcinoma (EAC), we examined its role in EAC development and its potential effect on chemosensitivity in the presence of selenium.
  • RESULTS: SELENBP1 expression decreased significantly in Barrett's esophagus to adenocarcinoma progression.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1150-8 [18281549.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1238-42 [19801978.001]
  • [Cites] Carcinogenesis. 2008 Nov;29(11):2175-81 [18676679.001]
  • [Cites] Mol Nutr Food Res. 2008 Nov;52(11):1289-99 [18435490.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 6;379(2):583-8 [19118533.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Genome Res. 2001 Mar;11(3):341-55 [11230159.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3062-70 [11306488.001]
  • [Cites] Annu Rev Nutr. 2001;21:453-73 [11375445.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20085-92 [11274215.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):156-64 [11782373.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Exp Dermatol. 2002 Oct;11(5):406-12 [12366693.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] J Natl Cancer Inst. 2003 May 21;95(10):750-7 [12759393.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2907-14 [12949386.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1883-94 [14625850.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):849-59 [14871960.001]
  • [Cites] J Pathol. 2004 Mar;202(3):321-9 [14991897.001]
  • [Cites] Carcinogenesis. 1988 Oct;9(10):1801-10 [3168159.001]
  • [Cites] Cancer Lett. 1988 Dec 15;43(3):227-36 [3203341.001]
  • [Cites] Carcinogenesis. 1990 Nov;11(11):2071-3 [2225343.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):595-600 [1824684.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):365-71 [1703038.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] Biochem Pharmacol. 1995 Jul 17;50(2):213-9 [7632165.001]
  • [Cites] J Cell Biochem. 1997 Feb;64(2):217-24 [9027582.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5571-8 [9407969.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3150-3 [9679983.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2379-88 [15788689.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2433-40 [16380993.001]
  • [Cites] Bioessays. 2006 Apr;28(4):378-86 [16547952.001]
  • [Cites] Electrophoresis. 2006 Apr;27(8):1683-91 [16532517.001]
  • [Cites] Proteomics. 2006 Jun;6(11):3466-76 [16645984.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1062-71 [17217624.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):355-61 [17237294.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):912-9 [17289885.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):2034-43 [17230520.001]
  • [Cites] Carcinogenesis. 2007 Apr;28(4):837-47 [17071627.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2484-90 [17724370.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2638-46 [19276359.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1576-85 [19156915.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jul;2(7):683-93 [19584079.001]
  • [ErratumIn] Clin Cancer Res. 2012 Jun 15;18(12):3490
  • (PMID = 20332323.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA071606; United States / NCI NIH HHS / CA / 5R01CA071606; United States / NCI NIH HHS / CA / 5K08CA127212; United States / NCI NIH HHS / CA / 5P30CA046592; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / CA071606-13; United States / NCI NIH HHS / CA / R01 CA071606-13; United States / NCI NIH HHS / CA / K08 CA134931; United States / NCI NIH HHS / CA / K08 CA127212-02; United States / NCI NIH HHS / CA / CA127212-02; United States / NCI NIH HHS / CA / K08 CA127212; United States / NCI NIH HHS / CA / 5K08CA134931; United States / NCI NIH HHS / CA / K08 CA134931-02; United States / NCI NIH HHS / CA / CA134931-02; United States / NCI NIH HHS / CA / CA084953-059001; United States / NCI NIH HHS / CA / U19 CA084953-059001; United States / NCI NIH HHS / CA / R01 CA154365
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SELENBP1 protein, human; 0 / Selenium-Binding Proteins
  • [Other-IDs] NLM/ NIHMS175714; NLM/ PMC2953959
  •  go-up   go-down


45. Thukkani N, Sonnenberg A: The influence of environmental risk factors in hospitalization for gastro-oesophageal reflux disease-related diagnoses in the United States. Aliment Pharmacol Ther; 2010 Apr;31(8):852-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oesophageal reflux and hiatal hernia were more common in female than in male inpatients, whereas Barrett's oesophagus and oesophageal adenocarcinoma were more common in male than in female inpatients.
  • Hospitalizations associated with oesophageal reflux, reflux oesophagitis and Barrett's oesophagus showed resembling geographical distributions among different US states.
  • [MeSH-minor] Aged. Barrett Esophagus / epidemiology. Barrett Esophagus / etiology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / etiology. Esophagitis, Peptic / epidemiology. Esophagitis, Peptic / etiology. Female. Hernia, Hiatal / epidemiology. Hernia, Hiatal / etiology. Humans. Male. Middle Aged. Prevalence. Risk Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102354.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


46. Zagaynova E, Gladkova N, Shakhova N, Gelikonov G, Gelikonov V: Endoscopic OCT with forward-looking probe: clinical studies in urology and gastroenterology. J Biophotonics; 2008 May;1(2):114-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity of EOCT cancer determination in Barrett's esophagus is from 71% to 85% at different stages of neoplasia with specificity 68% for all stages.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Colonic Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19343643.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


47. Béchade D, Blondon H, Sekkach Y, Desramé J, Algayres JP: [Review of the association between obesity and gastroesophageal reflux and its complications]. Gastroenterol Clin Biol; 2009 Mar;33(3):155-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophageal adenocarcinoma and its precursor Barrett's esophagus are increasing in incidence in western populations.
  • Studies about Barrett's esophagus in obese patients have emphasised the role of central adiposity as a stronger risk factor than BMI in the development of specialized intestinal metaplasia and subsequently esophagus adenocarcinoma.
  • Except cardiovascular diseases, type 2 diabetes and non alcoholic steatohepatitis, abdominal obesity and metabolic syndrome are responsible of an increase of prevalence of esophageal adenocarcinoma, but also other cancer sites.
  • [MeSH-minor] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Esophagitis, Peptic / etiology. Humans

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - GERD.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250782.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 143
  •  go-up   go-down


48. Souza RF, Krishnan K, Spechler SJ: Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol; 2008 Aug;295(2):G211-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acid, bile, and CDX: the ABCs of making Barrett's metaplasia.
  • Barrett's esophagus, a squamous-to-columnar cell metaplasia that develops as a result of chronic gastroesophageal reflux disease (GERD), is a risk factor for esophageal adenocarcinoma.
  • The molecular events underlying the pathogenesis of Barrett's metaplasia are poorly understood, but recent studies suggest that interactions among developmental signaling pathways, morphogenetic factors, and Caudal homeobox (Cdx) genes play key roles.
  • When mice are genetically engineered so that their gastric cells express Cdx, the stomach develops a metaplastic, intestinal-type epithelium similar to that of Barrett's esophagus.
  • Exposure to acid and bile has been shown to activate the Cdx promoter in certain esophageal cell lines, and Cdx expression has been found in inflamed esophageal squamous epithelium and in the specialized intestinal metaplasia of Barrett's esophagus.
  • Barrett's metaplasia must be sustained by stem cells, which might be identified by putative, intestinal stem cell markers like leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and doublecortin and CaM kinase-like-1 (DCAMKL-1).
  • Emerging concepts in tumor biology suggest that Barrett's cancers may develop from growth-promoting mutations in metaplastic stem cells or their progenitor cell progeny.
  • This report reviews the roles of developmental signaling pathways and the Cdx genes in the development of normal gut epithelia and the potential mechanisms whereby GERD may induce the esophageal expression of Cdx genes and other morphogenetic factors that mediate the development of Barrett's metaplasia.
  • [MeSH-major] Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Gastroesophageal Reflux / physiopathology. Homeodomain Proteins / physiology. Metaplasia / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556417.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX1 protein, human; 0 / CDX2 protein, human; 0 / Cdx2 protein, mouse; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Transcription Factors; EC 2.7.1.11 / DCLK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Number-of-references] 78
  •  go-up   go-down


49. da Rocha JR, Ribeiro U Jr, Sallum RA, Szachnowicz S, Cecconello I: Barrett's esophagus (BE) and carcinoma in the esophageal stump (ES) after esophagectomy with gastric pull-up in achalasia patients: a study based on 10 years follow-up. Ann Surg Oncol; 2008 Oct;15(10):2903-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus (BE) and carcinoma in the esophageal stump (ES) after esophagectomy with gastric pull-up in achalasia patients: a study based on 10 years follow-up.
  • This surgical technique has been associated to esophagitis and also Barrett's epithelium following esophagectomy.
  • AIM: To analyze late clinical, endoscopic, and pathologic findings in the esophageal stump (ES) mucosa after subtotal esophagectomy in patients treated for advanced chagasic achalasia.
  • RESULTS: The incidence of esophagitis in the esophageal stump (45.9% at 1 year; 71.9% at 5 years, and 70.0% at 10 years follow-up); gastritis in the transposed stomach (20.4% at 1 year, 31.0% at 5 years, and 40.0% at 10 or more years follow-up), and the occurrence of ectopic columnar metaplasia and Barrett's Esophagus in the ES (none until 1 year; 10.9% between 1 and 5 years; 29.5% between 5 and 10 years; and 57.5% at 10 or more years follow-up), all rose over time.
  • (1) Esophagitis and Barrett's esophagus in the esophageal stump rose over time. (2) These mucosal alterations and the development of squamous cell carcinoma and adenocarcinoma are probably due to exposure to duodenogastric reflux, and progressively higher acid output in the transposed stomach.
  • [MeSH-major] Barrett Esophagus / etiology. Esophageal Achalasia / surgery. Esophageal Neoplasms / etiology. Esophagectomy. Gastroplasty. Postoperative Complications
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Duodenogastric Reflux / complications. Duodenogastric Reflux / pathology. Duodenogastric Reflux / surgery. Esophagitis / etiology. Esophagitis / surgery. Female. Follow-Up Studies. Gastroesophageal Reflux / pathology. Gastroesophageal Reflux / surgery. Humans. Male. Middle Aged. Prognosis. Prospective Studies


50. Sud D, Zhong W, Beer DG, Mycek MA: Time-resolved optical imaging provides a molecular snapshot of altered metabolic function in living human cancer cell models. Opt Express; 2006 May 15;14(10):4412-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A fluorescence lifetime imaging microscopy (FLIM) method was developed and applied to investigate metabolic function in living human normal esophageal (HET-1) and Barrett's adenocarcinoma (SEG-1) cells.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19516593.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Al Madi MA: Barrett's esophagus: where do we stand? Saudi J Gastroenterol; 2009 Jan;15(1):2-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus: where do we stand?
  • Barrett's esophagus (BE) is a precursor for esophageal adenocarcinoma, which has an increased incidence rate over the last few decades.
  • Its importance stems from the poor five-year survival of esophageal adenocarcinoma and current data that suggest a survival benefit when surveillance programs are implemented.
  • The prevalence of BE in different geographic areas and the incidence of high-grade dysplasia and adenocarcinoma in this patient population is reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Gastroenterol. 2002 Sep;16(9):615-7 [12362216.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):225-9 [11774268.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):306-9 [11588545.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2005-12 [11467625.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3089-96 [11095322.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Mar;6(3):302-8 [18255349.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):533-7 [18047544.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):546-54 [17970838.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] Am J Gastroenterol. 2008 Feb;103(2):292-300 [17986313.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):394-8 [18045592.001]
  • [Cites] Endoscopy. 2008 Jan;40(1):16-22 [18058656.001]
  • [Cites] Dis Esophagus. 2008;21(1):43-50 [18197938.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):379-87 [18223212.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):92-7 [17764497.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):30-4 [18063419.001]
  • [Cites] ScientificWorldJournal. 2007;7:2046-71 [18167619.001]
  • [Cites] Yonsei Med J. 2007 Dec 31;48(6):1020-7 [18159596.001]
  • [Cites] Endoscopy. 2007 Dec;39(12):1086-91 [17701854.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Nov;19(11):969-75 [18049166.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1213-5 [18062074.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Digestion. 2007;75(4):227-31 [17986820.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1413-7, 1417.e1-2 [17997357.001]
  • [Cites] Endoscopy. 2007 Nov;39(11):948-51 [18008202.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1589-97 [17909921.001]
  • [Cites] Am J Gastroenterol. 2007 Nov;102(11):2380-6 [17640326.001]
  • [Cites] Dis Esophagus. 2007;20(6):516-22 [17958728.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2090-6 [17890521.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1395-402; discussion 1402 [17763917.001]
  • [Cites] Gastrointest Endosc. 2007 Oct;66(4):660-6; quiz 767, 769 [17905005.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):665-71; discussion 671-4 [17893503.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Sep;17(9):943-50 [16093872.001]
  • [Cites] Dis Esophagus. 2005;18(3):140-5 [16045573.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):671-8 [15855970.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):680-6 [15832094.001]
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):232-40 [15729231.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):21-6 [15654776.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1289-96 [15606390.001]
  • [Cites] J Pathol. 2005 Jan;205(1):57-64 [15586364.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):433-8; discussion 438-40 [10493489.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Jul;13(7):921-6 [10383527.001]
  • [Cites] Gastrointest Endosc. 1991 May-Jun;37(3):332-7 [2070985.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:71-80; discussion 95-6 [15456468.001]
  • [Cites] Lancet Oncol. 2004 Aug;5(8):497-508 [15288239.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Aug 15;20(4):399-406 [15298633.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Gut. 2004 Jun;53(6):785-90 [15138203.001]
  • [Cites] Gastrointest Endosc. 2004 May;59(6):655-8 [15114308.001]
  • [Cites] Med J Aust. 2004 Apr 19;180(8):387-91 [15089728.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):252-7 [15017665.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):998-1003 [14648410.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Jul;13(3):505-12 [14629106.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):325-34 [12916663.001]
  • [Cites] Can J Gastroenterol. 2003 May;17(5):313-7 [12772005.001]
  • [Cites] Aliment Pharmacol Ther. 2003 May 15;17(10):1319-24 [12755845.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):291-8 [12616111.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Dig Dis Sci. 2008 May;53(5):1175-85 [17939050.001]
  • [Cites] Am J Clin Nutr. 2008 Apr;87(4):949-56 [18400718.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):825-37 [18371146.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):850-5 [18371135.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):595-601 [18279860.001]
  • [Cites] Am J Epidemiol. 2008 Apr 1;167(7):839-46 [18218607.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):727-31 [18349295.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Oct;22(10):1650-5 [17845693.001]
  • [Cites] J Eval Clin Pract. 2007 Oct;13(5):789-94 [17824873.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Sep 15;26(6):913-23 [17767476.001]
  • [Cites] Dis Esophagus. 2006;19(2):84-7 [16643175.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Endoscopy. 2007 Sep;39(9):840-2 [17703397.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jun;22(6):908-12 [17565647.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Aug 1;26(3):501-7 [17635385.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):601-6 [17646787.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):594-8 [17611913.001]
  • [Cites] BMC Cancer. 2007;7:97 [17559672.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1154-61 [17433019.001]
  • [Cites] ScientificWorldJournal. 2007;7:449-65 [17450308.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):326-30 [17257905.001]
  • [Cites] Surg Endosc. 2007 Apr;21(4):625-8 [17364152.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2693-703 [17227516.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):60-6 [17185080.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1392-9 [17101315.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):867-72 [16981102.001]
  • [Cites] Am J Gastroenterol. 2006 Sep;101(9):1964-71 [16848802.001]
  • [Cites] Gut. 2006 Sep;55(9):1233-9 [16905695.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):195-9 [16860068.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1611-6 [16863568.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1416-20 [16863541.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1320-3 [16740562.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005 [16573802.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Feb;30(2):217-23 [16565653.001]
  • [Cites] Scand J Gastroenterol. 2006 Mar;41(3):349-56 [16497625.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7436-43 [16437713.001]
  • [Cites] Expert Rev Med Devices. 2005 Nov;2(6):713-23 [16293098.001]
  • [Cites] Dis Esophagus. 2005;18(5):291-7 [16197527.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):929-36 [16189764.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Scand J Gastroenterol. 2005 Jul;40(7):750-8 [16118910.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1206-11 [18619919.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):867-76 [18561930.001]
  • [Cites] J Clin Gastroenterol. 2008 Nov-Dec;42(10):1074-9 [18360296.001]
  • [Cites] Dig Dis Sci. 2008 Nov;53(11):2837-46 [18427992.001]
  • [Cites] Dig Dis Sci. 2008 Nov;53(11):2858-67 [18343998.001]
  • [Cites] Am J Gastroenterol. 2008 Sep;103(9):2333-40; quiz 2341 [18671819.001]
  • [Cites] J Gastrointest Surg. 2008 Oct;12(10):1646-54; discussion 1654-5 [18709511.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(4):741-50 [18656827.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(4):721-39 [18656826.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):24-31 [18442484.001]
  • [Cites] Gastrointest Endosc. 2008 Jul;68(1):35-40 [18355819.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jun;135(6):1220-7 [18544357.001]
  • [Cites] Ther Clin Risk Manag. 2007 Dec;3(6):1035-145 [18516262.001]
  • [Cites] Endoscopy. 2008 Jun;40(6):457-63 [18459090.001]
  • [Cites] Am J Gastroenterol. 2008 May;103(5):1079-89 [18445097.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3216-22 [18483390.001]
  • [Cites] Endoscopy. 2008 May;40(5):395-9 [18494133.001]
  • [Cites] Endoscopy. 2008 May;40(5):388-92 [18459075.001]
  • [Cites] Endoscopy. 2002 Dec;34(12):950-5 [12471537.001]
  • [Cites] Endoscopy. 2002 Dec;34(12):946-9 [12471536.001]
  • (PMID = 19568547.001).
  • [ISSN] 1319-3767
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2702947
  • [Keywords] NOTNLM ; Ablation / Barrett's esophagus / cancer / chemoprevention / dysplasia / esophagus / guidelines / imaging / screening / surveillance
  •  go-up   go-down


52. Sampliner RE, Camargo E, Prasad AR: Association of ablation of Barrett's esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia. Dis Esophagus; 2006;19(4):277-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of ablation of Barrett's esophagus with high grade dysplasia and adenocarcinoma of the gastric cardia.
  • There has been increasing application of endoscopic ablation therapy for patients with high-grade dysplasia (HGD) and Barrett's esophagus (BE).
  • Three cases are reported in which the patient developed adenocarcinoma of the gastric cardia after thermal ablation of HGD.
  • Biopsies documented adenocarcinoma of the gastric cardia.
  • The development of adenocarcinoma of the cardia is unexpected.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16866860.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ikeda K, Isomoto H, Oda H, Shikuwa S, Mizuta Y, Iwasaki K, Kohno S: Endoscopic submucosal dissection of a minute intramucosal adenocarcinoma in Barrett's esophagus. Dig Endosc; 2009 Jan;21(1):34-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection of a minute intramucosal adenocarcinoma in Barrett's esophagus.
  • A 73-year-old man with short segmental Barrett's esophagus underwent esophagoscopy, and a slightly depressed, discolored lesion was found on the anterior wall of the lower esophagus.
  • Under a provisional diagnosis of differentiated adenocarcinoma without local lymph node metastasis, endoscopic submucosal dissection (ESD) was carried out.
  • Histopathological examination confirmed intramucosal well-differentiated tubular adenocarcinoma without angiolymphatic invasion adjacent to the muscularis mucosae.
  • Considering that Barrett's esophagus is a precancerous condition, one may recommend eradication of both the neoplastic and non-neoplastic lesion with using ESD.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / complications. Esophageal Neoplasms / surgery

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691799.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


54. Peters JH: Getting it "just right": the continued dilemma of the ideal treatment of Barrett's esophagus with early neoplasia. Gastrointest Endosc; 2008 Apr;67(4):602-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Getting it "just right": the continued dilemma of the ideal treatment of Barrett's esophagus with early neoplasia.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Catheter Ablation / methods. Decision Making. Esophageal Neoplasms / therapy. Esophagectomy / methods. Photochemotherapy / methods

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gastrointest Endosc. 2008 Apr;67(4):595-601 [18279860.001]
  • (PMID = 18374023.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


55. Sharma P: Clinical practice. Barrett's esophagus. N Engl J Med; 2009 Dec 24;361(26):2548-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical practice. Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus. Esophagus / surgery. Gastroesophageal Reflux / surgery. Proton Pump Inhibitors / therapeutic use
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Algorithms. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / etiology. Esophagectomy. Esophagoscopy. Humans. Male. Middle Aged. Mucous Membrane / surgery. Obesity / complications. Omeprazole / therapeutic use

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2010 Apr 15;362(15):1448-9; author reply 1449 [20393183.001]
  • [ErratumIn] N Engl J Med. 2010 Apr 15;362(15):1450
  • (PMID = 20032324.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors; KG60484QX9 / Omeprazole
  • [Number-of-references] 47
  •  go-up   go-down


56. Dietz J, Chaves-E-Silva S, Meurer L, Sekine S, de Souza AR, Meine GC: Short segment Barrett's esophagus and distal gastric intestinal metaplasia. Arq Gastroenterol; 2006 Apr-Jun;43(2):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short segment Barrett's esophagus and distal gastric intestinal metaplasia.
  • BACKGROUND: Short segment Barrett's esophagus is defined by the presence of <3 cm of columnar-appearing mucosa in the distal esophagus with intestinal metaplasia on histophatological examination.
  • Barrett's esophagus is a risk factor to develop adenocarcinoma of the esophagus.
  • While Barrett's esophagus develops as a result of chronic gastroesophageal reflux disease, intestinal metaplasia in the gastric cardia is a consequence of chronic Helicobacter pylori infection and is associated with distal gastric intestinal metaplasia.
  • It can be difficult to determine whether short-segment columnar epithelium with intestinal metaplasia are lining the esophagus (a condition called short segment Barrett's esophagus) or the proximal stomach (a condition called intestinal metaplasia of the gastric cardia).
  • AIMS: To study the association of short segment Barrett's esophagus (length <3 cm) with gastric intestinal metaplasia (antrum or body) and infection by H. pylori.
  • PATIENTS AND METHODS: Eight-nine patients with short segment columnar-appearing mucosa in the esophagus, length <3 cm, were studied.
  • Gastric intestinal metaplasia (antrum or body) was diagnosed in 21 from 42 (50.0%) patients in the group with esophageal intestinal metaplasia and 7 from 47 (14.9%) patients in the group with esophageal columnar appearing mucosa but without intestinal metaplasia.
  • CONCLUSION: Intestinal metaplasia is a frequent finding in patients with <3 cm of columnar-appearing mucosa in the distal esophagus.
  • [MeSH-major] Barrett Esophagus / pathology. Gastroesophageal Reflux / pathology. Helicobacter Infections / pathology. Intestines / pathology. Stomach / pathology


57. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R: Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia; 2007 Mar;9(3):236-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression.
  • Esophageal Barrett's adenocarcinoma (BA) develops through a multistage process, which is associated with the transcriptional silencing of tumor-suppressor genes by promoter CpG island hypermethylation.
  • In this study, we explored the promoter hypermethylation and protein expression of proapoptotic death-associated protein kinase (DAPK) during the multistep Barrett's carcinogenesis cascade.
  • Hypermethylation of DAPK promoter was detected in 20% of normal mucosa, 50% of Barrett's metaplasia, 53% of dysplasia, and 60% of adenocarcinomas, and resulted in a marked decrease in DAPK protein expression (P < .01).
  • Thus, we consider DAPK inactivation by promoter hypermethylation as an early event in Barrett's carcinogenesis and suggest that a decreased protein expression of DAPK likely plays a role in the development and progression of BA.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):1-7 [11146619.001]
  • [Cites] Cancer Lett. 2006 Aug 18;240(1):69-75 [16246486.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2847-51 [11306456.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1765-70 [11313923.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):590-1 [11845806.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1113-21 [11910361.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1511-6 [10995806.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):135-41 [15185075.001]
  • [Cites] Dig Dis. 2004;22(2):126-33 [15383753.001]
  • [Cites] Dig Dis. 2004;22(2):196-201 [15383761.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):736-40 [15471559.001]
  • [Cites] Genes Dev. 1995 Jan 1;9(1):15-30 [7828849.001]
  • [Cites] EMBO J. 1997 Mar 3;16(5):998-1008 [9118961.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):180-4 [9367156.001]
  • [Cites] EMBO J. 1998 Apr 15;17(8):2426-35 [9545253.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):218-28 [10381931.001]
  • [Cites] J Cell Biol. 1999 Jul 12;146(1):141-8 [10402466.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1493-500 [15870861.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):331-5 [15967110.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1763-7 [16009322.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6544-9 [16166431.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2113-7 [16172218.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):733-40 [16075282.001]
  • [Cites] J Pathol. 2006 May;209(1):95-105 [16575786.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • (PMID = 17401463.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / CA106176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  • [Other-IDs] NLM/ PMC1838580
  •  go-up   go-down


58. Gossner L: The role of endoscopic resection and ablation therapy for early lesions. Best Pract Res Clin Gastroenterol; 2006;20(5):867-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic resection (ER) has gained more and more importance in the treatment of early neoplastic lesions in Barrett's oesophagus over the last few years.
  • A recently described method of EMR comprises the circumferential mucosal incision with a special type of needle-knife and subsequent en-bloc resection following prior injection under the lesions, but only a few patients with early Barrett's cancer were treated so far.
  • EMR should be considered as the treatment of choice for high-grade intraepithelial neoplasia (HGIN) and mucosal adenocarcinoma in Barrett's oesophagus.
  • Curative endoscopic treatment of early neoplastic lesions in Barrett's oesophagus should only be carried out in centers with a high-volume.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Catheter Ablation. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagoscopy
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Carcinoma in Situ / etiology. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997166.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


59. Rossi E, Grisanti S, Villanacci V, Della Casa D, Cengia P, Missale G, Minelli L, Buglione M, Cestari R, Bassotti G: HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med; 2009 Sep;13(9B):3826-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.
  • Barrett's oesophagus (BO) is the primary precursor lesion for oesophageal adenocarcinoma (ADC).
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Gene Expression Regulation, Neoplastic. Receptor, ErbB-2 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292734.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC4516530
  •  go-up   go-down


60. Chandrasoma P: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2005 Apr;46(4):361-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies of the cardiac mucosa and Barrett's oesophagus.
  • Confusion regarding the diagnosis of Barrett's oesophagus exists because of a false dogma that cardiac mucosa is normally present in the gastro-oesophageal junctional region.
  • Recent data indicate that the only normal epithelia in the oesophagus and proximal stomach are squamous epithelium and gastric oxyntic mucosa.
  • When this fact is recognized, it becomes easy to develop precise histological definitions for the normal state (presence of only squamous and oxyntic mucosa), metaplastic oesophageal columnar epithelium (cardiac mucosa with and without intestinal metaplasia, and oxynto-cardiac mucosa), the gastro-oesophageal junction (the proximal limit of gastric oxyntic mucosa), the oesophagus (that part of the foregut lined by squamous and metaplastic columnar epithelium), reflux disease (the presence of metaplastic columnar epithelium), and Barrett's oesophagus (cardiac mucosa with intestinal metaplasia).
  • It is also possible to assess accurately the severity of reflux which is directly proportional to the amount of metaplastic columnar epithelium, and the risk of adenocarcinoma which is related to the amount of dysplasia in intestinal metaplastic epithelium present within the columnar lined segment of the oesophagus.
  • Histopathological precision cannot be matched by any other modality and can convert the confusion that exists regarding diagnosis of Barrett's oesophagus to complete lucidity in a manner that is simple, accurate, and reproducible.
  • [MeSH-major] Barrett Esophagus / pathology. Cardia / pathology. Gastric Mucosa / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):97-8; author reply 98 [16842257.001]
  • (PMID = 15810947.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


61. Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, DeMeester TR: Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg; 2006 Apr;202(4):588-96; discussion 596-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients.
  • The aim of this study was to assess the modern outcomes of esophagectomy for adenocarcinoma.
  • STUDY DESIGN: We studied 263 consecutive patients (215 men, 48 women), who had esophagectomy for adenocarcinoma from 1992 to 2002.
  • RESULTS: Seventeen percent (44 of 263) of the patients were identified in a Barrett's surveillance program.
  • The frequency of T1N0 adenocarcinoma increased over the study period (p=0.024).
  • CONCLUSIONS: Nearly half of patients undergoing esophagectomy for adenocarcinoma survive >or=5 years.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571425.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Dvorakova K, Payne CM, Ramsey L, Bernstein H, Holubec H, Chavarria M, Bernstein C, Sampliner RE, Riley C, Prasad A, Garewal H: Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues. Am J Gastroenterol; 2005 Feb;100(2):424-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis resistance in Barrett's esophagus: ex vivo bioassay of live stressed tissues.
  • BACKGROUND AND AIMS: Barrett's esophagus (BE) is a premalignant lesion of the distal esophagus in which squamous epithelial cells are replaced by metaplastic intestinal-like columnar epithelium that contains goblet cells.
  • The factors that contribute to the progression from normal squamous mucosa to BE, Barrett's dysplasia, and adenocarcinoma are not well understood at the molecular level.
  • Altogether, the data indicate that reduced apoptosis capability in BE tissue may contribute to progression to esophageal adenocarcinoma.
  • [MeSH-major] Apoptosis / drug effects. Barrett Esophagus / pathology. Deoxycholic Acid / pharmacology. Esophagus / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Caspase 3. Caspases / analysis. Colon / pathology. Epithelium / drug effects. Epithelium / pathology. Humans. Immunohistochemistry. In Vitro Techniques. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Keratins / analysis. Microscopy, Electron, Transmission. Middle Aged

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667503.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA 95060; United States / NCI NIH HHS / CA / CA 23074; United States / NCI NIH HHS / CA / CA 72008; United States / NIEHS NIH HHS / ES / ES 06694
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 005990WHZZ / Deoxycholic Acid; 68238-35-7 / Keratins; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


63. Sharma P, Wani S, Bansal A: The quest for intestinal metaplasia--is it worth the effort? Am J Gastroenterol; 2007 Jun;102(6):1162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Starting with the basics, the definition and diagnosis of Barrett's esophagus (BE) continues to be a point of major debate globally leading to definitions that have been restrictive (requiring histologically confirmed intestinal metaplasia) or all-encompassing (simply the presence of CLE at endoscopy).
  • The interest in intestinal metaplasia stems from studies that have consistently demonstrated intestinal metaplasia and dysplasia both adjacent to and remote from esophageal adenocarcinoma.
  • The proponents of not requiring histology suggest that if a sufficient number of biopsies is obtained over an adequate period of time, intestinal metaplasia can usually be demonstrated in such cases and that the true neoplastic potential of the cardiac and fundic-type mucosa detected in the CLE has not been delineated.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biopsy. Diagnostic Imaging. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Gastric Mucosa / pathology. Humans. Metaplasia. Precancerous Conditions / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2007 Jun;102(6):1154-61 [17433019.001]
  • (PMID = 17531009.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


64. Zaninotto G, Minnei F, Guirroli E, Ceolin M, Battaglia G, Bellumat A, Betetto G, Bozzola L, Cassaro M, Cataudella G, Dal Bò N, Farinati F, Florea G, Furlanetto A, Galliani E, Germanà B, Guerini A, Macrì E, Marcon V, Mastropaolo G, Meggio A, Miori G, Morelli L, Murer B, Norberto L, Togni R, Valiante F, Rugge M: The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. Dig Liver Dis; 2007 Jan;39(1):18-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results.
  • BACKGROUND: The natural history of Barrett's Oeosphagus is not completely clarified and Barrett's Oeosphagus Registries are considered useful tools to expand our knowledge on this disease.
  • A Barrett's Oeosphagus Registry has been therefore established in the Veneto Region and neighbouring provinces.
  • AIMS: The aims of the Registry are to assess the demographical, endoscopical and histological characteristics of Barrett's Oeosphagus patients; the prevalence of non-invasive neoplasia and Barrett's Adenocarcinoma and the timing and incidence of Barrett's Oeosphagus progression to malignancy.
  • METHODS: An interdisciplinary committee of endoscopists, pathologists and information technology experts was established in 2004 to design a website-based Barrett's Oesophagus Registry for the Veneto Region and neighbouring north-eastern Italian provinces.
  • RESULTS: In the first 18 months, 397 patients with endoscopically visible and histologically proven Barrett's Oeosphagus were enrolled in the Registry; the median age of these patients was 66 years (male:female=3:1).
  • Most patients (75%) had a Short Segment of Barrett's Oesophagus (<or=3 cm) and only 1 in 4 had a Long Segment of Barrett's Oesophagus (>3 cm).
  • Long Segment of Barrett's Oesophagus patients were 5 years older than the Short Segment of Barrett's Oesophagus patients (p<0.05), suggesting a progression from Short Segment of Barrett's Oesophagus to Long Segment of Barrett's Oesophagus.
  • Though no data are available on the incidence of non-invasive neoplasia or Barrett's Adenocarcinoma (i.e., progression to cancer at least 12 months after enrolment), the prevalence of neoplastic lesions (found within 12 months of enrolment) was 5% for Short Segment of Barrett's Oesophagus and 19% for Long Segment of Barrett's Oesophagus, indicating that a careful multiple-biopsy endoscopic protocol is needed, especially when Long Segment of Barrett's Oesophagus are suspected at endoscopy.
  • The prevalence of Barrett's Adenocarcinoma among patients with non-invasive neoplasia was 1/17 cases of low-grade non-invasive neoplasia and 2/3 cases of high-grade non-invasive neoplasia, indicating that these patients require strict endoscopic and bioptic follow-up.
  • CONCLUSION: A regional Barrett's Oeosphagus Registry is feasible at a relatively low cost and enables significant data to be collected in a relatively short time.
  • [MeSH-major] Barrett Esophagus. Esophagoscopy. Precancerous Conditions / diagnosis. Prevalence. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141593.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Dumot JA, Greenwald BD: Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC's of ablative techniques. Endoscopy; 2008 Dec;40(12):1026-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of endoscopic ablation modalities are available for the treatment of Barrett's esophagus.
  • Multiple studies have evaluated the use of argon plasma coagulation, mostly in nondysplastic Barrett's esophagus.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Cryosurgery / methods. Esophageal Neoplasms / surgery. Esophagoscopy / methods. Laser Coagulation / methods. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065487.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


66. Jenkins GJ, Mikhail J, Alhamdani A, Brown TH, Caplin S, Manson JM, Bowden R, Toffazal N, Griffiths AP, Parry JM, Baxter JN: Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J Clin Pathol; 2007 Nov;60(11):1232-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers.
  • AIMS: To determine if immunohistochemistry (IHC) could be used to monitor nuclear factor-kappaB (NF-kappaB) activity in oesophageal adenocarcinoma and pre-malignant (Barrett's) oesophageal tissues, relative to normal oesophageal mucosa.
  • I-kappaB (another NF-kappaB target) showed down-regulation in dysplastic and adenocarcinoma tissues.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Interleukin-8 / metabolism. NF-kappa B / metabolism
  • [MeSH-minor] Barrett Esophagus / metabolism. Carrier Proteins / metabolism. Disease Progression. Humans. Polymerase Chain Reaction / methods. Precancerous Conditions / metabolism. Transcription Factor RelA / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1019-23 [16205698.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1257-64 [15929754.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):588-90 [11845805.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):824-37 [12081731.001]
  • [Cites] Gut. 2002 Sep;51(3):316-22 [12171950.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2294-303 [12431991.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):317-23 [14656946.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):491-500 [15024310.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1075-83 [15387324.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Lancet. 1994 Dec 3;344(8936):1533-6 [7983953.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Pathobiology. 1999;67(1):12-8 [9873223.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):717-25 [10370600.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6938-47 [10602468.001]
  • (PMID = 17220207.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Interleukin-8; 0 / NF-kappa B; 0 / Transcription Factor RelA
  • [Other-IDs] NLM/ PMC2095472
  •  go-up   go-down


67. Canto MI: Barrett's esophagus. Gastrointest Endosc Clin N Am; 2005 Jan;15(1):83-92, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus.
  • The evaluation of Barrett's esophagus (BE) with EUS is indicated only when there is high-grade dysplasia or a concern for malignancy in an endoscopic lesion.
  • Because the options for the management of BE and early adenocarcinoma are diverse, proper selection of patients by accurate staging with EUS is critical, particularly when nonoperative management is considered.
  • This article discusses the scientific evidence for the use of EUS in BE or early esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Barrett Esophagus / ultrasonography. Endosonography / methods. Esophageal Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15555953.001).
  • [ISSN] 1052-5157
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


68. Razvi MH, Peng D, Dar AA, Powell SM, Frierson HF Jr, Moskaluk CA, Washington K, El-Rifai W: Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. Genes Chromosomes Cancer; 2007 Oct;46(10):914-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression.
  • In our efforts to define gene expression alterations in Barrett's-related adenocarcinomas (BA), we produced eight SAGE libraries and obtained a total of 457,894 expressed tags with 32,035 (6.9%) accounting for singleton tags.
  • In addition, we performed an immunohistochemistry analysis for ANPEP, which demonstrated overexpression of ANPEP in 6/7 (86%) Barrett's dysplasias and 35/65 (54%) BAs.
  • ANPEP is a secreted protein that may have diagnostic and/or prognostic significance for Barrett's progression.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Transcription, Genetic
  • [MeSH-minor] Antigens, CD13 / genetics. Antigens, CD13 / metabolism. Esophageal Neoplasms / genetics. Esophageal Neoplasms / metabolism. Expressed Sequence Tags. Female. Gastric Mucosa / metabolism. Gene Library. Humans. Immunoenzyme Techniques. Intestinal Neoplasms / genetics. Intestinal Neoplasms / metabolism. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17636545.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 95103; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


69. Seewald S, Ang TL, Groth S, Zhong Y, Bertschinger P, Altorfer J, Thonke F, Soehendra N: Detection and endoscopic therapy of early esophageal adenocarcinoma. Curr Opin Gastroenterol; 2008 Jul;24(4):521-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and endoscopic therapy of early esophageal adenocarcinoma.
  • PURPOSE OF REVIEW: This review summarizes recent progress on endoscopic diagnosis and treatment of esophageal high-grade intraepithelial neoplasia and early adenocarcinoma and critically analyzes the literature in the context of preexisting scientific data.
  • The type of mucosal and capillary patterns seen on narrow band imaging predicted the presence of specialized intestinal metaplasia, high-grade intraepithelial neoplasia and early adenocarcinoma.
  • Endoscopic radiofrequency ablation of Barrett's mucosa did not cause strictures and buried glandular mucosa.
  • Localized and radical or complete circumferential endoscopic mucosa resections were effective therapies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Endoscopy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622170.001).
  • [ISSN] 1531-7056
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


70. Katz PO: Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther; 2005 Dec;22 Suppl 3:31-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, patients may experience sleep disturbances that can potentially lead to complications such as erosive oesophagitis and Barrett's oesophagus, and may be a risk factor for development of oesophageal adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / prevention & control. Barrett Esophagus / prevention & control. Delayed-Action Preparations / administration & dosage. Disease Progression. Esophageal Neoplasms / prevention & control. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - GERD.
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303035.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors; KG60484QX9 / Omeprazole
  • [Number-of-references] 37
  •  go-up   go-down


71. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA: Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer; 2005 Sep 10;116(4):584-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
  • Hypermethylation of secreted frizzled-related proteins (SFRP) genes frequently occurs with several cancers but has not been studied in esophageal adenocarcinoma or its precursor-Barrett's esophagus.
  • To explore the role of SFRP methylation in the neoplastic progression of Barrett's esophagus and to evaluate methylated SFRP genes as biomarkers for Barrett's esophagus and cancer, methylation of SFRP genes was determined in esophageal adenocarcinomas, Barrett's esophagus and normal epithelia using methylation-specific PCR.
  • The mRNA expression of SFRP genes was quantified by real-time reverse-transcription PCR in esophageal adenocarcinoma cell lines with and without demethylation by 5-aza-2'deoxycytidine and inhibition of deacetylation by trichostatin A treatment.
  • Hypermethylation of SFRP1, 2, 4 and 5 was detected in 93%, 83%, 73% and 85% of 40 cancers; 81%, 89%, 78% and 73% of 37 Barrett's epithelia; 25%, 64%, 32% and 21% of 28 adjacent normal epithelia from Barrett's patients; and 10%, 67%, 0% and 13% of 30 normal esophagogastric epithelia from healthy individuals, respectively (p < 0.001 for SFRP1, 4 and 5; p < 0.05 for SFRP2).
  • Thus, hypermethylation of SFRP genes is a common early event in the evolution of esophageal adenocarcinoma, and methylation of SFRP1, 4 and 5 might serve as biomarkers for Barrett's neoplasia.
  • Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Methylation. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Eye Proteins / genetics. Eye Proteins / metabolism. Gene Expression Profiling. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Membrane Proteins / genetics. Membrane Proteins / metabolism. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15825175.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eye Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / SFRP1 protein, human; 0 / SFRP4 protein, human; 0 / SFRP5 protein, human
  •  go-up   go-down


72. Kruijshaar ME, Kerkhof M, Siersema PD, Steyerberg EW, Homs MY, Essink-Bot ML, CYBAR Study Group: The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Endoscopy; 2006 Sep;38(9):873-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus.
  • BACKGROUND AND STUDY AIMS: Patients with Barrett's esophagus are recommended to undergo regular surveillance with upper gastrointestinal endoscopy, an invasive procedure that may cause anxiety, pain, and discomfort.
  • PATIENTS AND METHODS: A total of 192 patients with Barrett's esophagus were asked to fill out questionnaires at 1 week and immediately before endoscopy, and at 1 week and 1 month afterwards.
  • (iii) psychological burden, i. e., anxiety, depression and distress levels (Hospital Anxiety and Depression scale, Impact of Event Scale); and (iv) perceived risk of developing adenocarcinoma.
  • Patients perceiving their risk of developing adenocarcinoma as high reported higher levels of psychological distress and that the procedure was a greater burden.
  • CONCLUSIONS: Upper gastrointestinal endoscopy is burdensome for many patients with Barrett's esophagus and causes moderate distress.
  • Perception of a high risk of adenocarcinoma may increase distress and the burden experienced from the procedure.
  • The benefits of endoscopic surveillance for patients with Barrett's esophagus should be weighed against its drawbacks, including the short-term burden for patients.
  • [MeSH-major] Barrett Esophagus / diagnosis. Cost of Illness. Endoscopy, Gastrointestinal
  • [MeSH-minor] Adenocarcinoma / diagnosis. Aged. Esophageal Neoplasms / diagnosis. Female. Humans. Male. Middle Aged. Stress, Psychological

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019759.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Feagins LA, Souza RF: Molecular targets for treatment of Barrett's esophagus. Dis Esophagus; 2005;18(2):75-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targets for treatment of Barrett's esophagus.
  • The major risk factors for esophageal adenocarcinoma are gastroesophageal reflux disease (GERD) and its sequela, Barrett's esophagus.
  • In a minority of patients however, ongoing GERD leads to replacement of esophageal squamous mucosa with metaplastic, intestinal-type Barrett's mucosa.
  • In the setting of continued peptic injury, Barrett's mucosa can give rise to esophageal adenocarcinoma.
  • Despite the widespread use of potent acid suppressive therapies for patients with GERD, the incidence of esophageal adenocarcinoma, among white men in the USA, the UK and Europe has continued to rise.
  • Cancers in Barrett's esophagus arise through a sequence of genetic events that endow the cells with six essential physiologic hallmarks of cancer as described by Hanahan and Weinberg in 2000.
  • While the acquisition of these essential attributes is not specific to the neoplastic progression of Barrett's esophagus, this review will focus on the genetic alterations that occur in Barrett's cells that contribute to the acquisition of each of the hallmarks.
  • Moreover, potential diagnostic and therapeutic strategies for Barrett's patients aimed at each of these cancer hallmarks will be reviewed.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053481.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 5T32DK-07745; United States / NIDDK NIH HHS / DK / DK63621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Inhibitors
  • [Number-of-references] 111
  •  go-up   go-down


74. Pech O, Ell C: Is vagal-sparing esophagectomy ideal for Barrett's esophagus with intramucosal adenocarcinoma or high-grade dysplasia? Nat Clin Pract Gastroenterol Hepatol; 2008 Jun;5(6):302-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is vagal-sparing esophagectomy ideal for Barrett's esophagus with intramucosal adenocarcinoma or high-grade dysplasia?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg. 2007 Oct;246(4):665-71; discussion 671-4 [17893503.001]
  • (PMID = 18431373.001).
  • [ISSN] 1743-4386
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Takubo K, Aida J, Sawabe M, Arai T, Kato H, Pech O, Arima M: The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endoscopy. Best Pract Res Clin Gastroenterol; 2008;22(4):569-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of primary oesophageal adenocarcinoma in Caucasian men has recently been increasing rapidly.
  • Therefore, primary oesophageal adenocarcinoma, columnar-lined oesophagus (CLO) or Barrett's oesophagus and the normal condition of the lower segment of the oesophagus are currently receiving worldwide attention in the medical field.
  • We review definitions of the OGJ, the pattern of the squamocolumnar junction (SCJ), oesophageal cardiac-type glands beneath the squamous epithelium, the normal squamous epithelium, columnar islands in squamous-lined mucosa, squamous islands in CLO and newly reported metaplastic changes in the OGJ zone.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Esophagogastric Junction / cytology. Intestinal Mucosa / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656817.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


76. Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ: Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol; 2009 Jun;7(6):613-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in patients with Barrett's esophagus: a systematic review.
  • BACKGROUND & AIMS: Barrett's esophagus (BE) affects approximately 10% of patients with chronic gastroesophageal reflux disease (GERD).
  • Patients with BE are at risk for reduced health-related quality of life (HRQoL) associated with GERD, in addition to the potential psychosocial stress of carrying a diagnosis of a premalignant condition with a risk of esophageal adenocarcinoma.
  • In addition, patients with BE are at risk for psychological consequences such as depression, anxiety, and stress, which may be related to their increased risk of esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 2001;64(3):151-4 [11786662.001]
  • [Cites] Am J Med. 2001 Jul;111(1):33-7 [11448658.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):48-53 [11961604.001]
  • [Cites] Am J Gastroenterol. 2002 Sep;97(9):2193-200 [12358232.001]
  • [Cites] Am J Gastroenterol. 2003 Mar;98(3 Suppl):S8-S14 [12644026.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):880-5 [12618934.001]
  • [Cites] J Hypertens. 2003 Jul;21(7):1283-9 [12817174.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1487-93 [12873567.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Oct 15;18(8):767-76 [14535869.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1193-9 [12799881.001]
  • [Cites] Dig Dis. 2004;22(2):108-14 [15383750.001]
  • [Cites] Br J Psychiatry. 1976 Mar;128:280-9 [1252693.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] N Engl J Med. 1985 Oct 3;313(14):857-9 [4033716.001]
  • [Cites] Gastroenterology. 1987 Jan;92(1):118-24 [3781178.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Med Care. 1993 Mar;31(3):247-63 [8450681.001]
  • [Cites] Scand J Gastroenterol Suppl. 1993;199:18-21 [8171293.001]
  • [Cites] J Clin Epidemiol. 1995 Jan;48(1):167-71 [7853043.001]
  • [Cites] Br J Surg. 1995 Feb;82(2):216-22 [7749697.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1448-56 [9136821.001]
  • [Cites] Dig Dis. 1998 Sep-Oct;16(5):315-24 [9892791.001]
  • [Cites] Eur J Surg Suppl. 1998;(583):41-9 [10027672.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2017-21 [10445522.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2033-6 [10445524.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2037-42 [10445525.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] Thorax. 1953 Jun;8(2):87-101 [13077502.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):524-33 [15743346.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):577-80 [15743354.001]
  • [Cites] Hepatology. 2005 Apr;41(4):790-800 [15791608.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):429-36 [16083700.001]
  • [Cites] Dig Liver Dis. 2005 Sep;37(9):651-8 [15919250.001]
  • [Cites] J Am Board Fam Pract. 2005 Sep-Oct;18(5):393-400 [16148249.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] J Clin Gastroenterol. 2006 Feb;40(2):109-15 [16394870.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Feb 1;23(3):371-6 [16422996.001]
  • [Cites] Health Qual Life Outcomes. 2006;4:45 [16884539.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):873-8 [17019759.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):16-25 [17185075.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):26-30 [17185076.001]
  • [Cites] Dis Esophagus. 2007;20(2):130-4 [17439596.001]
  • [Cites] Qual Life Res. 2007 Oct;16(8):1309-18 [17634755.001]
  • [Cites] Lancet. 2008 Mar 1;371(9614):709-10 [18313491.001]
  • [Cites] Mayo Clin Proc. 2002 Apr;77(4):371-83 [11936935.001]
  • [Cites] Hepatology. 1999 Nov;30(5):1299-301 [10534353.001]
  • [Cites] JAMA. 2000 Apr 19;283(15):2008-12 [10789670.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1881-7 [10950030.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):285-97 [11232666.001]
  • [Cites] Ann Pharmacother. 2002 Apr;36(4):605-11 [11918506.001]
  • (PMID = 19281858.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007634; None / None / / T32 DK007634-09; United States / NIDDK NIH HHS / DK / T32 DK 07634; United States / NIDDK NIH HHS / DK / T32 DK007634-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS102432; NLM/ PMC2693470
  •  go-up   go-down


77. Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, McGuigan J, Comber H, Reynolds JV, Murray LJ: The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology; 2009 Mar;136(3):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
  • BACKGROUND & AIMS: Alcohol consumption may increase gastroesophageal reflux symptoms, cause damage to the esophageal mucosa, and/or promote carcinogenesis.
  • However, reports about the association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma are conflicting.
  • METHODS: Information relating to alcohol consumption, at age 21 and 5 years before the interview date, was collected from 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma patients and 260 frequency-matched population controls.
  • No associations were observed between total alcohol consumption 5 years before the interview date and reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma (OR, 1.26, 0.78-2.05; OR, 0.72, 0.43-1.21; and OR, 0.75, 0.46-1.22, respectively).
  • Total alcohol consumption at age 21 years was significantly associated with reflux esophagitis (OR, 2.24, 1.35-3.74) but not with Barrett's esophagus or esophageal adenocarcinoma (OR, 1.06, 0.63-1.79 and OR, 1.27, 0.77-2.10, respectively).
  • More recent alcohol consumption does not appear to confer any increased risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Alcohol Drinking / epidemiology. Barrett Esophagus / epidemiology. Esophageal Neoplasms / epidemiology. Esophagitis, Peptic / epidemiology


78. Weimann A, Rieger A, Zimmermann M, Gross M, Hoffmann P, Slevogt H, Morawietz L: Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus. Virchows Arch; 2010 Nov;457(5):537-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.
  • In esophageal neoplasms, the histopathologic differentiation between Barrett's esophagus with or without intraepithelial neoplasia and adenocarcinoma is often challenging.
  • The expression of CDX2, LI-cadherin, mucin 2 (MUC2), blood group 8 (BG8, Lewis(y)), claudin-2, and villin was investigated in normal gastroesophageal (n = 23) and in Barrett's (n = 17) mucosa, in low-grade (n = 12) and high-grade (n = 9) intraepithelial neoplasia (IEN) as well as in esophageal adenocarcinoma (n = 16), using immunohistochemistry.
  • For CDX2 and LI-cadherin, the immunoreactivity score was highest in IEN while for MUC2, BG8, and villin, it dropped gradually from Barrett's via IEN to adenocarcinoma, and expression of Claudin-2 was only weak and focal in all lesions.
  • MUC2 and LI-cadherin are useful immunohistochemical markers for the differentiation between normal glandular mucosa, Barrett's mucosa, IEN, and invasive carcinoma of the esophagus; however, none of the examined markers was helpful for the differentiation between low-grade and high-grade IEN.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers, Tumor / analysis. Esophageal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1565-77 [12404231.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1353-69 [8207063.001]
  • [Cites] Exp Cell Res. 2009 Jun 10;315 (10 ):1779-89 [19371634.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):316-24 [12692197.001]
  • [Cites] J Cell Biol. 1987 Jul;105(1):359-69 [2440895.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):562-8 [15178443.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Cancer Sci. 2003 May;94(5):425-30 [12824888.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1442-7 [14576477.001]
  • [Cites] J Cell Sci. 1997 Mar;110 ( Pt 5):663-71 [9092948.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] J Cell Biol. 1999 Nov 15;147(4):891-903 [10562289.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 24;300(4):813-8 [12559945.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):53-7 [2912874.001]
  • [Cites] J Gastroenterol. 2003;38(1):14-22 [12560917.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 May;46(2):187-206 [12711361.001]
  • [Cites] Protein Eng. 1996 May;9(5):447-59 [8795045.001]
  • [Cites] Dis Esophagus. 2008;21(1):43-50 [18197938.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] J Gastroenterol. 2002;37(2):94-100 [11871772.001]
  • [Cites] Gut. 2001 Jul;49(1):73-81 [11413113.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1569-91 [12016424.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):357-9 [11331951.001]
  • [Cites] Int J Surg Pathol. 2010 Oct;18(5):330-7 [20444732.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):618-24 [14623315.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):740-6 [7833053.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Indian J Cancer. 2007 Jan-Mar;44(1):1-5 [17401217.001]
  • [Cites] Hum Pathol. 1992 May;23(5):475-6 [1568742.001]
  • [Cites] J Pathol. 2005 Apr;205(5):615-22 [15732140.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):961-8 [16133365.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):431-45 [15750830.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):525-31; discussion 531-3 [7574932.001]
  • [Cites] Biochem Cell Biol. 1998;76(6):957-69 [10392709.001]
  • [Cites] Med Electron Microsc. 2003 Sep;36(3):147-56 [14505058.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):619-25 [8552090.001]
  • [Cites] Br J Surg. 1950 Oct;38(150):175-82 [14791960.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] J Histochem Cytochem. 2005 Jan;53(1):75-85 [15637340.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):937-43 [10201460.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:136-43 [11193569.001]
  • (PMID = 20844891.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH17 protein, human; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / CLDN2 protein, human; 0 / Cadherins; 0 / Claudins; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Mucin-2; 0 / villin
  •  go-up   go-down


79. Huang Q, Hardie LJ: Biomarkers in Barrett's oesophagus. Biochem Soc Trans; 2010 Apr;38(2):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in Barrett's oesophagus.
  • Biomarkers are needed to screen multiple stages in the clinical pathway of Barrett's oesophagus patients; from disease diagnosis to risk stratification and predicting response to therapy.
  • The majority of Barrett's oesophagus patients remain undiagnosed in the general population.
  • In order to develop a tool to screen for Barrett's oesophagus in the primary care setting, minimally invasive sampling methods coupled with immunocytology-based biomarkers are currently being assessed.
  • Biomarkers are also being developed to improve detection of high-grade dysplasia and oesophageal adenocarcinoma, utilizing brush cytology combined with FISH (fluorescence in situ hybridization), and to assess therapeutic success and risk of complication during photodynamic therapy.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / genetics. Biomarkers / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298180.001).
  • [ISSN] 1470-8752
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C11347
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Pharmacological
  • [Number-of-references] 50
  •  go-up   go-down


80. Fleischer DE, Odze R, Overholt BF, Carroll J, Chang KJ, Das A, Goldblum J, Miller D, Lightdale CJ, Peters J, Rothstein R, Sharma VK, Smith D, Velanovich V, Wolfsen H, Triadafilopoulos G: The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci; 2010 Jul;55(7):1918-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus.
  • Non-dysplastic mucosa (ND-) in Barrett's esophagus (BE) shows clonal molecular aberrations, loss of cell cycle control, and other features of "neoplasia."
  • Some studies show substantial progression rates of low-grade dysplasia (LGD), and crypt dysplasia, to esophageal adenocarcinoma (EAC).
  • Radiofrequency ablation (RFA) is a safe and effective method for removing mucosa at risk of cancer.
  • [MeSH-major] Barrett Esophagus / pathology. Barrett Esophagus / surgery. Catheter Ablation / methods. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Adenocarcinoma / surgery. Biopsy, Needle. Endoscopy / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / prevention & control. Esophageal Neoplasms / surgery. Esophagoscopy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Randomized Controlled Trials as Topic. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2010 Jul;55(7):1811-4 [20544388.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2292-5 [8162566.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Jun;278(6):G1000-9 [10859231.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):169-90 [16299787.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 Mar;139(3):713-6 [20074750.001]
  • [Cites] Ann Thorac Surg. 1998 Dec;66(6):1886-93 [9930464.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Dis Esophagus. 2007;20(6):497-503 [17958725.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] N Engl J Med. 2009 Dec 24;361(26):2548-56 [20032324.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95 [10601379.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):222-5 [9040195.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):765-70 [16550596.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Lab Invest. 2007 May;87(5):466-72 [17310216.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005 [16573802.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1327-35 [18670357.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1805-11 [11078757.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1769-76 [1360434.001]
  • [Cites] Arch Pathol Lab Med. 2008 Oct;132(10):1577-85 [18834215.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):727-33 [16556174.001]
  • [Cites] Am J Gastroenterol. 1988 Mar;83(3):291-4 [3125739.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23 [19281858.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1356-62 [19491849.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):258-63 [15017666.001]
  • [Cites] Gut. 2005 Aug;54(8):1062-6 [15857935.001]
  • [Cites] Am J Gastroenterol. 2009 Apr;104(4):816-24 [19293780.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Feb 1;31(3):440-51 [19843025.001]
  • [Cites] Keio J Med. 2009 Mar;58(1):12-8 [19398879.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):412-8 [10208462.001]
  • [Cites] Gastrointest Endosc. 2010 Jan;71(1):147-66 [19879565.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Mar;15(3):269-76 [11207503.001]
  • [Cites] Surg Oncol Clin N Am. 2009 Jul;18(3):453-67 [19500736.001]
  • [Cites] Am J Gastroenterol. 2009 Oct;104(10):2588-94 [19623166.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):652-9 [9708927.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] Clin Gastroenterol Hepatol. 2010 Jan;8(1):7-9 [19788932.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):226-9 [16362470.001]
  • (PMID = 20405211.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 106
  •  go-up   go-down


81. Ilyas S, DeMars CJ, Buttar NS: Chemoprevention in Barrett's esophagus. J Gastrointest Cancer; 2007;38(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention in Barrett's esophagus.
  • Barrett's metaplasia-associated esophageal adenocarcinoma is one of the most rapidly increasing cancers in Western countries.
  • Carcinogenesis in Barrett's mucosa is a multistep process in which cellular growth becomes progressively dysregulated.
  • In this review, we will discuss various potential chemoprevention targets and rationale behind their use to prevent Barrett's related esophageal adenocarcinoma.
  • We will also critically appraise the emerging preclinical and clinical literature regarding prevention of neoplasia in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / prevention & control. Chemoprevention / methods. Precancerous Conditions / prevention & control

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1884-6 [15447745.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):193-4 [9040189.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Jun;278(6):G1000-9 [10859231.001]
  • [Cites] Neoplasia. 1999 Jun;1(2):145-53 [10933049.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G991-7 [16081761.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):237-42 [11315258.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7987-91 [11753681.001]
  • [Cites] Mod Pathol. 1997 Dec;10(12):1201-8 [9436964.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Am J Gastroenterol. 1996 Mar;91(3):511-5 [8633500.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):975-82 [14608530.001]
  • [Cites] Int J Cancer. 1995 Jan 3;60(1):27-32 [7814148.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1468-70 [15887128.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Carcinogenesis. 2002 Dec;23(12):2095-102 [12507933.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G18-27 [16935849.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1531-6 [10910955.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Eur J Pharmacol. 1996 Apr 4;300(1-2):147-50 [8741181.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):106-12 [16265072.001]
  • [Cites] Mutat Res. 1995 Jun;339(2):73-89 [7791803.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1753-63 [11058618.001]
  • [Cites] Biochem Pharmacol. 1999 Sep 15;58(6):911-5 [10509743.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005 [16573802.001]
  • [Cites] J Gastrointest Surg. 1998 Jul-Aug;2(4):333-41 [9841990.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1391-9 [11729118.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4588-95 [8007963.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Surgery. 2001 Mar;129(3):267-76 [11231454.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:54-9 [14725580.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4784-92 [15269153.001]
  • [Cites] Lab Invest. 1996 Aug;75(2):263-72 [8765326.001]
  • [Cites] Am J Gastroenterol. 1993 Mar;88(3):402-8 [8438848.001]
  • [Cites] Compr Ther. 1987 Jun;13(6):57-60 [3581748.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Mayo Clin Proc. 2001 Apr;76(4):438-46 [11322362.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1867-73 [8934532.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):288-93 [16492917.001]
  • [Cites] Am J Med. 2001 Dec 3;111 Suppl 8A:130S-136S [11749938.001]
  • [Cites] Gastroenterology. 1994 Sep;107(3):747-54 [8076761.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):257-63 [10657966.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):327-35 [10419913.001]
  • [Cites] Br J Surg. 1997 Jan;84(1):21-8 [9043441.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):545-9 [10868686.001]
  • [Cites] Recent Results Cancer Res. 2005;166:35-46 [15648181.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97 [12916666.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1248-57 [11984511.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):551-5 [12447994.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1707-9 [15470193.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Br J Surg. 1997 Jan;84(1):119-25 [9043475.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):677-82 [8751234.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):575-80 [12384802.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1075-83 [15387324.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):652-9 [9708927.001]
  • [Cites] Med J Aust. 2004 Apr 19;180(8):387-91 [15089728.001]
  • [Cites] Surgery. 1995 Jun;117(6):699-704 [7778033.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Jun;7(3):196-201 [15913478.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):434-8 [10821489.001]
  • (PMID = 19065715.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA110022-01; United States / NIDDK NIH HHS / DK / DK076845-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


82. Falkenback D, Nilbert M, Oberg S, Johansson J: Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis Esophagus; 2008;21(2):97-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased understanding of the molecular processes associated with the dysplasia-adenocarcinoma sequence linked to Barrett's esophagus may be beneficial for early tumor detection and refined diagnosis as well as for improved prognostication.
  • We applied immunohistochemical staining for the markers Ki-67, p53, beta-catenin and E-cadherin in order to evaluate their prognostic importance in 59 Barrett's esophagus-associated adenocarcinomas.
  • The down-regulation of E-cadherin and its prognostic importance indicate that cell adhesion may be a prime area for targeted therapies in esophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269642.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


83. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE: Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol; 2006 May;4(5):566-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
  • BACKGROUND & AIMS: The exact incidence of adenocarcinoma in patients with Barrett's esophagus (BE) is not known and is reported to vary from 0.2%-2% per year.
  • Of the 34 patients developing HGD and/or cancer, 18 patients (53%) had at least 2 initial consecutive endoscopies with biopsies revealing nondysplastic mucosa.
  • At least half the patients who developed HGD and/or cancer had 2 consecutive initial endoscopies with biopsies revealing nondysplastic mucosa.
  • [MeSH-major] Adenocarcinoma / epidemiology. Barrett Esophagus / pathology. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / pathology. Precancerous Conditions / pathology


84. Rajendra S, Robertson IK: Barrett's oesophagus; acid and the human papilloma virus? J Clin Virol; 2009 Feb;44(2):176
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's oesophagus; acid and the human papilloma virus?
  • [MeSH-major] Adenocarcinoma / etiology. Barrett Esophagus / complications. Esophageal Neoplasms / etiology. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Virol. 2008 Oct;43(2):250-2 [18718811.001]
  • (PMID = 19119064.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


85. McFadden DW, Riggs DR, Jackson BJ, Cunningham C: Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms. Oncol Rep; 2008 Feb;19(2):563-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms.
  • We hypothesized that IP6 would inhibit the cell growth rate of Barrett's adenocarcinoma in vitro.
  • Two Barrett's-associated adenocarcinoma cell lines, SEG-1 and BIC-1, were treated with IP6 at 0.5, 1.0 and 5.0 mM concentrations.
  • Our findings suggest that IP6 has the potential to become an effective adjunct for Barrett's adenocarcinoma.
  • Further studies are needed to evaluate safety and clinical utility of this agent in patients with Barrett's adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Barrett Esophagus / pathology. Cell Proliferation / drug effects. Esophageal Neoplasms / pathology. Phytic Acid / pharmacology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202808.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbohydrates; 7IGF0S7R8I / Phytic Acid
  •  go-up   go-down


86. von Rahden BH, Stein HJ, Weber A, Vieth M, Stolte M, Rösch T, Schmid RM, Sarbia M, Meining A: Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. Dis Esophagus; 2008;21(8):685-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database.
  • Endoscopic surveillance is recommended for patients with Barrett's esophagus (BE).
  • Detection of 'malignant Barrett' (either high-grade intra-epithelial neoplasia or invasive adenocarcinoma) was considered as study end-point.
  • 'Malignant Barrett' was detected in 28 cases (1.9%) during a median follow-up period of 24 months (1-255), accounting for an incidence of 0.95% per patient year of follow-up.
  • The frequency of 'malignant Barrett' was significantly higher (P < 0.001, chi(2)-test) in the LG-IN group (n = 11, 19.3%) compared with the non-neoplastic BE group (n = 17, 1.2%).
  • In the non-neoplastic BE group, 'malignant Barrett' was predominantly found during re-endoscopy within the first year of follow-up (12 of 17; 70.6%), in contrast to the LG-IN group, in which 'malignant Barrett' was observed predominantly after a time exceeding 12 months (8 of 11, 72.7%; P = 0.05, Fisher's exact test).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847456.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Grassi A, Giannarelli D, Iacopini F, Paoluzi P, Iannetti A, Giovannelli L, Efrati C, Barberani F, Giovannone M, Tosoni M: Prevalence of intestinal metaplasia in the distal esophagus in patients endoscopically suspected for short Barrett's esophagus. J Exp Clin Cancer Res; 2006 Sep;25(3):297-302